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Summary
Intra-tumor heterogeneity is a widely demonstrated characteristic of human malignancies
(Hanahan and Weinberg, 2011). Despite this, cells that became malignant because of onco-
genic driven mutations still rely on their sustained over-expression for survival (Weinstein
and Joe, 2006). The concept of oncogene dependence has been the base for modern targeted
therapy, which, unfortunately still cannot completely eradicate the disease.
Resistance to targeted therapy might be elicited by mechanisms that cause genomic insta-
bility, which is a striking feature of both solid and haemapoietic human tumors (Duijf et al.,
2012). The importance of chromosome instability (CIN) is underscored by its association
with poor patient outcome in diﬀerent cancer types, including breast (McGranahan et al.,
2012). Furthermore, CIN has been shown to facilitate tumor relapse when found in primary
tumors (Sotillo et al., 2010).
CIN can be elicited by several molecular mechanisms (Holland and Cleveland, 2012). Among
those, over-activation of the mitotic checkpoint - in particular through the up-regulation of
the Mad2 protein - has been frequently observed in a variety of human tumors, including
breast (Rhodes et al., 2007). Characterization of the molecular mechanisms responsible for
tumor relapse has become a major focus in cancer, and the relevance of CIN in patient's
prognosis and survival suggests that the CIN status could be exploited in the clinical setting
(Holland and Cleveland, 2012; Pfau and Amon, 2012).
The work presented here focuses on the study of breast cancer, which is worldwide one
of the leading causes of death in women. Interestingly, CIN scores are prognostic in certain
subgroups (Smid et al., 2011); among those, Her2 positive breast tumors, are characterized
by extremely poor outcome.
Given the lack of available CIN mouse models of breast tumorigenesis, we generated new
mouse models that would allow us to:
 Faithfully model human disease by introducing CIN into established mouse models of
breast cancer,
 Study the role of CIN in breast tumor initiation, progression and relapse,
 Understand the molecular mechanisms of cancer relapse in the face of CIN.
The study of these mouse models lead to the following conclusions:
 In the Her2 and c-MYC oncogenic backgrounds, Mad2 over-expression plays a dual
opposing role in breast tumorigenesis: tumor suppressing in primary tumor formation
while accelerating tumor recurrence,
 Mad2 over-expression promotes tumor heterogeneity,
 Mad2 induced heterogeneity in the primary tumor gives the possibility to choose among
diﬀerent mechanisms of relapse.
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Resumen
Una de las principales características del cáncer en humanos es la heterogeneidad intra-
tumoral (Hanahan and Weinberg, 2011). Las células que adquieren características to-
morogénicas debido a determinadas mutaciones necesitan mantener la sobreexpresión de
oncogenes para su supervivencia (Weinstein and Joe, 2006). La dependencia oncogénica ha
sido la base de la terapia dirigida que, desafortunadamente aún no ha sido capaz de erradicar
la enfermedad. Esta resistencia a la terapia puede explicarse a través de mecanismos que
causan inestabilidad cromosómica (CIN). Dicha CIN adquiere mayor importancia si consi-
deramos su asociación con la mala prognosis de los pacientes. (McGranahan et al., 2012).
Se ha demostrado que la CIN presente en tumores primarios es capaz de promover recidivas
(Sotillo et al., 2010). Varios mecanismos moleculares pueden dar lugar a CIN (Holland and
Cleveland, 2012). Entre ellos, la sobreactivación del punto de control mitótico en particular
a través de la sobreexpresión de Mad2- se ha encontrado en una gran variedad de tumores
humanos, entre ellos el cáncer de mama (Rhodes et al., 2007). La relevancia de la CIN en
la prognosis y supervivencia de los pacientes sugiere que podría ser explotada para el diseño
de nuevas terapias en clínica (Holland and Cleveland, 2012; Pfau and Amon, 2012). Este
trabajo se centra en el estudio del cáncer de mama. Los niveles de CIN son indicadores de
la prognosis de determinados subgrupos (Smid et al., 2011), siendo extremadamente grave
en los tumores de mama positivos para Her2. Dada la falta de modelos para estudiar la CIN
en tumorogenesis de mama, hemos generado una batería de modelos que nos han permitido:
 Modelar la tumorogenesis humana mediante la introducción de inestabilidad cromosómi-
ca en modelos murinos ya establecidos para el estudio del cáncer de mama,
 El estudio del papel que la CIN cumple en la iniciación, progresión y aparición de
recidivas tumorales,
 Entender los mecanismos moleculares de las recidivas tumorales en presencia de in-
estabilidad cromosómica.
El estudio con los modelos animales presentados en este estudio llevaron a las siguientes
conclusiones:
 en escenarios de sobreexpresión de los oncogenes Her2 y c-MYC durante la tumorogé-
nesis de mama, la sobreexpresión de Mad2 juega un papel dual: actúa como supresor
en la formación de tumores primarios pero actúa como promotor en la aparición de
recidivas tumorales,
 La sobreexpresión de Mad2 promueve la heterogeneidad tumoral,
 La heterogeneidad de los tumores primarios debida a la sobreexpresión de Mad2, otorga
la posibilidad de elegir entre diversos mecanismos promotores de recidivas tumorales.
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Preface
The origin of the word cancer dates back to Ancient Greece. The Greek physician Hyp-
pocrates (460-370 BC) the Father of Medicine, was the ﬁrst using the words carcinos and
carcinoma to deﬁne non-ulcer and ulcer forming tumors (American Cancer Society®).
To the best of our knowledge, cancer and human beings have always co-existed and the
very ﬁrst evidence can be found among human mummies and fossilized tumors of the bone
tissue. The Edwin Smith surgical papyrus (3000-2500 BC, Ancient Egypt), the oldest known
surgical treatise on trauma, is the earliest written prove of cancer description. One of the
cases concerning ailments of the soft tissue of the breast describes buldging tumors and was
classiﬁed with unfavorable prognosis. If the diagnosis reported that the tumors had spread
over the breast, were cool to the touch and buldging (The University of Chicago, The ori-
ental institute. http://oi.uchicago.edu/), no treatment would help. This appears to have
been based on established practice.
How far are we now from the non-treatable disease described more than 5000 years ago?
Since then, research has made immense improvements in understanding the biology and con-
sequent potential tumor treatment. There is an enormous body of literature that supports
the hypothesis of cancer developing as a multistep disease, where diﬀerent somatic mutations
must be acquired in order for a cell to become tumorigenic. Six distinct, but complementary,
biological capabilities fuelling transformation have been identiﬁed and deﬁned as hallmarks
of cancer (Hanahan and Weinberg, 2000). All of them allow malignant cells to survive in
conditions that would inevitably lead to death in normal cells.
Albeit the hallmarks constitute an organizing principle to reconcile the intricacies of the
neoplastic disease, the main obstacle is within the term cancer itself. Cancer is not a unique
disease, but it encompasses a multitude of heterogeneous tumor types.
Underlying this, are the next generation of cancer hallmarks (Hanahan and Weinberg, 2011):
new emerging attributes (evading immune response and altering energy metabolism) and en-
abling characteristics (inﬂammation and genome instability).
Since Theodor Boveri (1862-1915) postulated that cancer cells may arise from single cells
with abnormal chromosome complement (seminal treatise Zur Frage der Entstehung Ma-
ligner Tumoren), the role of chromosome instability (CIN) in tumorigenesis has been a
central question in cancer biology. In fact, genome instability can generate the genetic di-
versity required to accelerate traditional hallmarks acquisition and, consequently, help the
selection of drug resistant clones.
The work presented in this thesis focuses on CIN - a dynamic state in which cells con-
tinuously gain or lose whole, or parts of, chromosomes - which is a common type of genome
instability, present both in solid and hematopoietic human tumors.
In particular, its role in breast tumorigenesis, from tumor initiation to progression and re-
lapse will be presented and discussed.
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Chapter 1
Introduction
1.1 The Mad2 (mitotic arrest deﬁcient 2) protein
1.1.1 The eukaryotes cell cycle
A basic eukaryotic cell cycle consists of four phases: the gap before DNA replication (G1),
the DNA synthetic phase (S), the gap after DNA replication (G2) and the mitotic phase (M)
which culminates in cell division. Since no dramatic morphological changes can be observed,
the G1, S and G2 phases are collectively known as interphase. Cells in G1 can, before pass-
ing the restriction point and therefore commit to DNA replication (Pardee, 1974), enter a
resting state called G0. In mammals, most of the adult cells are in a quiescent phase named
G0. Active proliferation is a prerogative of specialized cells only, such as certain ones the
gut epithelium or the hematopoietic system.
The quiescent phase is a reversible state - with the only exception being terminally diﬀeren-
tiated cells. In fact, the presence of speciﬁc mitogenic signals allow cells in G0 to re-enter the
cell cycle and resume proliferation and division programs. As soon as the restriction point
(Pardee, 1974) in G1 is reached and passed, cells are committed to replicate their genome
and complete mitosis.
Diﬀerent cellular proteins tightly regulate the transition from one cell phase to another.
These are cyclins and their partners CDKs (cyclin-dependent kinases). CDKs are a family
of serine/threonine protein kinases that are temporally and speciﬁcally activated during the
cell cycle. Only ﬁve out of nine known CDKs are active during the cell cycle: CDK4, CDK6
and CDK2 during G1, CDK2 in S, and CDK1 along G2 and M phases (Figure 1). As CDKs
protein levels do not vary during the cell cycle, their activity is controlled by the presence,
or absence, of their activating subunits, named cyclins. In contrast, cyclins levels rise and
fall during the cell cycle, since protein availability is controlled by ubiquitin-mediated pro-
teasome degradation at the end of the phase they are required for (Figure 1) (Glotzer et al.
1991; Rechsteiner and Rogers, 1996). This way, they can periodically activate partner CDKs
(Evans et al. 1983; Pines and Hunter 1991). Speciﬁc types of cyclins are required to activate
partner deﬁned CDKs to allow progression through the diﬀerent phases (Figure 1). For this
dissertation, it is important to highlight the interaction between cyclin B and CDK1, which
regulates the late events of mitosis. Once CDKs are activated, they induce downstream
signaling via phosphorylation of target proteins and make the progression through the cycle
possible (Morgan, 1995).
Cyclin binding is an essential prerequisite for CDK activation; however, their activity is
controlled as well by phosphorylation or dephosphorylation events on conserved threonine
and tyrosine residues (Harper et al. 1995; Paulovich and Hartwell, 1995). Furthermore, two
distinct classes of CDK inhibitors (CKI) have been discovered: the INK4 family and the
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Figure 1.1: Progression through the mammalian cell cycle. The phases of a cell cycle are shown.
Cells may enter in quiescence (dotted loop, G0 phase) during the G1 phase before reaching the restriction
point (dotted line). The progressive activation of cyclin-CDK complexes during the diﬀerent phases of the
cell cycle is also indicated. Re-entry into the cell cycle from quiescence is mediated by cyclin D-CDK4 and
cyclin D-CDK6 complexes. Cyclin E-CDK2 complexes are active in late G1 phase. S phase is characterized
by the activation of cyclin A-CDK2. Cyclin A-CDK1 and cyclin B-CDK1 complexes are active during the
G2 and M phases. During G1, Rb is phosphorylated and inactivated by cyclin D-CDK4, cyclin D-CDK6
and cyclin E-CDK2 complexes. (Figure adapted from (Coller H.A., 2007)).
Cip/Kip family (Sherr and Roberts, 1995). They regulate CDK activity by binding either
to CDK alone or to already formed CDK-cyclin complexes. Ultimately, diﬀerent cell cycle
regulating proteins speciﬁcally regulate cell cycle progression via their intracellular localiza-
tion (Heald et al., 1993; Sanchez et al., 1997).
Cyclin protein levels are not only regulated by their degradation. In particular, the E2F
family of transcription factors regulate, among other targets, cyclin A and E and CDK1 ex-
pression (Ren et al. 2002). In addition, the E2F family is target of the Rb (retinoblastoma)
tumor suppressor, the ﬁrst ever to be identiﬁed. Rb activity is regulated by post-translation
phosphorylation of conserved residues. When in its active form, Rb binds to E2F and pre-
vents the transcription of target genes that are essential for the G1 to S transition. However,
in early G1, Rb is phosphorylated by cyclin D/CDK6, cyclin D/CDK4 complexes and, later,
cyclin E/CDK2 or cyclin A/CDK2 thus being converted in its inactive form. E2F transcrip-
tion factors are released and can freely drive the expression of genes essential for later cell
cycle phases and DNA duplication. Rb phosphorylation is regulated by extracellular mito-
gen signals, bridging its tumor suppressive function to cellular proliferation. Thereof, it is
of no surprise that the Rb pathway is disrupted in most tumors. Whereas it is mutated
only in speciﬁc tumor types (i.e. osteosarcoma, retinoblastoma. . . ), increasing evidence has
supported deregulation in its activity - through cross-talking signaling pathways - in most
of the tumors. Rb deregulated or deﬁcient cells are usually eliminated through p53 media-
ted apoptosis, since this would allow unscheduled entry into S phase and represent a major
danger towards tumor formation. As a consequence, in many tumors both the Rb and p53
pathways are conjointly disrupted to sustain malignant cell growth and uncontrolled division.
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As relevant for this dissertation, it is important to mention that E2F transcription factors
regulate not only cell cycle genes, but also the expression of the Mad2 (mitotic arrest de-
ﬁcient 2) gene (see 1.2.1). The Mad2 protein is the focus of this work and is an essential
component of the SAC (spindle assembly checkpoint, see 1.2.1). Its role, function and conse-
quences of deregulated expression will be described in detail in the next sections. Hernando
et al. (Hernando et al., 2004) ﬁrst demonstrated that Mad2 is, indeed, a direct target of
E2F. Consequently - as E2F activity is controlled by Rb - deregulated expression of Mad2 is
linked to Rb pathway defects in human patients. Thereof, Rb deﬁciency not only promotes
uncontrolled cell cycle progression, but also genomic instability (see 1.2.2).
1.1.1.1 The mitotic process
Mitosis is the cell cycle phase during which a mother cell duplicates into two genetically
identical daughter cells. It was ﬁrst discovered in the early 1880s by Walter Flemming, who
originally coined this term from the Greek word for thread, reﬂecting the shape of mitotic
chromosomes.
Since errors or failure in mitosis generate daughter cells with an abnormal chromosome com-
plement, it is a complex, delicate and highly regulated process.
According to morphological features of the cell, mitosis can be subdivided into ﬁve diﬀerent
phases: prophase, prometaphase, metaphase, anaphase and telophase. After the duplicated
genome has been correctly distributed and packed into a newly formed nuclear membrane,
the mother cell ﬁnally divides into two daughter cells in a process known as cytokinesis (from
the greek cyto - cell - and kinesis - motion).
After genome replication in S phase, sister chromatids condensation marks the onset of
prophase. Concurrently, the mitotic spindle begins taking shape via the migration of du-
plicated centrosomes to opposite sides of the mother cell. Prometaphase begins when the
nuclear envelope disintegrates and microtubules invade the nuclear space (open mitosis).
Sister chromatids are still associated at the centromeric region and multiprotein complexes,
called cohesin, help preventing their premature separation (Haering al., 2008). In the mean-
time, the formation of the mitotic spindle, a symmetrical microtubule-based structure, takes
place. In metaphase, the chromosomes have completed congression to the equatorial plate of
the spindle, forming the so-called metaphase plate, and are attached to robust microtubules
ﬁbers. In anaphase, the sister chromatids have lost cohesion and segregate towards opposite
poles of the spindle. At late anaphase, the spindle elongates separating furthermore the two
groups of chromatids. In telophase, chromosomes reach the opposite poles of the spindle,
chromatin starts to decondense and the nuclear envelope reforms around the two masses of
chromatin.
Finally cytokinesis, the process of cytoplasmatic cell division occurs. It starts during anaphase
and progresses through telophase with the assembly of a contractile ring at the cell cortex.
This protein ﬁlament structure deﬁnes the midbody at the equator of the cell and, while
shrinking, forms the so-called cleavage furrow. The complete separation of the cytoplasm
into the two daughter cells marks the termination of the whole process.
1.2 The cell cycle checkpoints
In 1989, Hartwell and Weinert (Hartwell and Weinert, 1989) postulated the existence of
dependent relationships during the cell cycle. They hypothesized that the completion of
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late events in the cell cycle must have depended on the correct fulﬁllment of earlier events;
only in this case, the correct order of proceedings could be ensured.
Control mechanisms enforcing dependency in the cell cycle (Hartwell and Weinert, 1989)
were, for the ﬁrst time, named checkpoints. In this paper, they gave direct evidence for the
existence of a DNA damage checkpoint in S. cerevisiae. At the same time, they postulated
the presence of a dependency of anaphase on metaphase. The control mechanism was hinted
by the following observation: whenever a delay in chromosome alignment at the metaphase
plate would occur, anaphase was prevented as long as all chromosomes correctly aligned at
the plate.
Few years later, two diﬀerent laboratories (Hoyt al., 1991; Li and Murray, 1991) identiﬁed a
feedback control preventing exit from mitosis as long as the mitotic spindle was completely
formed. Again in S. cerevisiae, the use of drugs inhibiting microtubule polymerization led
to the discovery of two genes: Mad (Mitotic arrest deﬁcient) and Bub (Budding inhibited
by Benzimidazole). These mutant strains were viable as long as mitosis would normally be
completed. However, Mad mutants were not able to delay cell division when treated with
benomyl and cells were killed only when passing through nuclear division. This suggested
that the absence of a functional mitotic spindle was the lethal event when attempting to se-
gregate chromosomes. These studies proved the existence of a Spindle Assembly Checkpoint
(SAC) or Mitotic Checkpoint (MC) in budding yeast. We are now aware that its function is
to prevent metaphase to anaphase transition as long as all chromosomes are correctly aligned
at the metaphase plate and all kinetochores have made connections with the microtubules
of the spindle apparatus. Consequently, the SAC ensures accurate chromosome segregation.
Given its function, in most metazoans the SAC is a constitutive essential pathway - con-
served from yeast to mammals (Benezra and Li, 1996) - whose abrogation causes genomic
instability as well as cell and organismal death if happening at early developmental stages.
However, while the SAC is needless in organisms such as S. cerevisiae or D. melanogaster
under conditions in which the normal completion of mitosis is not undermined, it is essen-
tial in all normal or transformed mammalian cells at every cell division. Hence, genomic
abnormalities in human tumors are not likely to be caused by complete SAC abrogation
(Schvartzman et al., 2010).
1.2.1 The mitotic checkpoint
Since the Mad2 protein and the mitotic checkpoint are the main focus of this work, the aim
of this section will be to give an outline and discuss its main players.
The function of the mitotic checkpoint is to monitor chromosome segregation by delay-
ing anaphase until all chromosomes have become bipolarly attached to the mitotic spindle.
Key proteins, essential for mitotic checkpoint signaling, are: Mad1, Mad2, Bub3, and the
kinases Bub1 and BubR1. During the early mitotic phases, all of them are at least tem-
porarily localized to unattached kinetochores. The principal target of the SAC machinery
is the anaphase promoting complex/cyclosome (APC/C), an SCF E3 ubiquitin ligase whose
activity is required for the metaphase to anaphase transition. The MC functions as an in-
hibitory signal that delays APC/C activation.
In order for mitosis to be completed, two proteins must be eliminated: cyclin B (see para-
graph 1.1) and securin. These are both APC targets and undergo ubiquitin-mediated protea-
somal degradation; the F-box subunit regulating target speciﬁcity is, in this case, the Cdc20
protein (Wang et al., 2013). Cyclin B is the activating partner of the mitotic kinase CDK1,
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which is required to enter and maintain mitosis. CDK1 activity decreases following cyclin B
degradation, and this event allows transition to late mitotic phases and their fulﬁllment.
At this phase of mitosis, sister chromatids are still connected at the kinetochores through co-
hesins, multiprotein ring complexes which prevent their premature separation. Consequently,
their elimination is essential to allow chromosome segregation. The protein separase speci-
ﬁcally targets cohesins, upon removal of its stochiometric inhibitor securin. Therefore, the
SAC prevents both mitotic exit pathways activation - by stabilizing cyclin B - and premature
loss of sister-chromatids cohesion prior to correct attachment to the mitotic spindle keeping
the protease separase in its inactive state.
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Figure 1.2: The mitotic checkpoint: the guardian of accurate chromosome segregation. Left
panel: to prevent chromosome missegregation and aneuploidy, cells have evolved a surveillance pathway
known as the mitotic checkpoint that prevents metaphase to anaphase transition until all chromosomes have
bipolarly attached to the mitotic spindle. Unattached kinetochores release a diﬀusible signal that inhibits
ubiquitination of cyclin B and securin by the APC/Cdc20 ligase. Middle panel: at metaphase, when all
kinetochores are correctly attached, the mitotic checkpoint is silenced and APC/Cdc20 ubiquitinates securin
and cyclin B1, thereby targeting them for proteasome degradation. Right panel: destruction of securin frees
separase, which promotes sister chromatid separation, and cyclin B1 degradation inactivates CDK1, thus
promoting exit from mitosis. (Figure taken from (Holland and Cleveland, 2012)).
Trying to rule out how the SAC machinery works has been a great challenge since the
past decade, and, still, we do not have full understanding of it.
It has been widely demonstrated that the sensor of the SAC is the Mad2 protein. It is
recruited to the kinetochores by Mad1, via interaction with its N-terminal domain. The
Mad2/Mad1 complex is a stochiometric tetramer which disappears from kinetochores upon
microtubule attachment. The ﬁrst model that tried to explain how the SAC works was
proposed by Luo et al. (Luo et al., 2004) and was deﬁned as the exchange model. One
year later, the Mad1/Mad2 complex was proposed to act as a primer for Mad2 activation
(De Antoni et al., 2005). In fact, the Mad2 protein adopts two conformations: open Mad2
(O-Mad2) and closed Mad2 (C-Mad2), diﬀering for a structural change in the C-terminal
segment. Only when in complex with Cdc20 or Mad1, Mad2 adopts the closed conformation.
As conformational changes require energy expenditure, kinetochore localized Mad1 was hy-
pothesized to favor the transition from O-Mad2 to C-Mad2 and, at the same time, act as
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a receptor for O-Mad2. When converted into the closed conformation, Mad2 is shued in
complex with the Cdc20 F-box protein. In this model, Mad1/C-Mad2 acts as a template
to generate a structural equivalent Cdc20/C-Mad2 copy and, for the ﬁrst time, provides a
mechanism for ampliﬁcation of the SAC signal in distance from the kinetochores.
Further implementation of this model came a few years later (Kulukian et al., 2009). Di-
rect evidence that unattached kinetochores can catalytically generate a diﬀusible Cdc20
inhibitor or inhibit Cdc20 already bound to APC/C was given. In this case, unattached
kinetochores act directly on Mad2 to amplify the wait signal and Mad2 dimerization is re-
quired for kinetochore ampliﬁcation of Cdc20 inhibition. Thereof, C-Mad2/Cdc20 represents
a precursor to promote exchange of Cdc20 onto BubR1. Next, Bub3 binding generates the
Cdc20/BubR1/Bub3 complex which prevents cyclin B ubiquitination both when Cdc20 is
bound to the APC/C and also precluding its binding to the E3 enzyme. As Mad2 was never
co-puriﬁed with the Cdc20/BubR1/Bub3 complex, its presence might not be constitutive
but may act as a shuing component.
At the same time, the SAC is regulated by the inhibitory activity of p31comet (Yang et al.,
2007). In particular, this protein has a structural fold that closely mimics that of C-Mad2
and is, therefore, able to compete for the binding at the dimerization interface of Mad2.
This way, it antagonizes the Mad1-assisted structural modiﬁcation of Mad2 and promotes
the disruption of C-Mad2/Cdc20 complexes. p31comet role controls checkpoint activation and
gives a potential explanation for rapid checkpoint inactivation once all SAC conditions are
satisﬁed.
The nature of the exact signal sensed by the SAC machinery is still under investigation.
On one hand, the proof of SAC proteins recruitment to unattached kinechores perfectly
ﬁts with the hypothesis of SAC activation by unattached kinetochores themselves (Rieder
et al., 1994; Li and Nicklas 1995). On the other, what is still a mystery is the ability
to distinguish between correct and incorrect attachments, such as synthelic ones. In this
case, kinetochores are attached to a correct number of microtubules but emanating from
the same spindle pole - instead of opposite ones. Shall we consider microtubules as pulling
ropes, they should not only provide an all or nothing attachment signal, but generate
a certain tension between sister kinetochores when chromatids start segregating towards
opposite spindle poles. If the degree of tension is not correct, the SAC may be able to
discriminate among correct and incorrect microtubule-kinetochore attachments. Whether
the SAC is hold active by an activating signal - in case of incorrect attachments - or shut
down in the presence of bipolar attachments is still not clear. At the same time, we still
do not know if these two scenarios may coexist or be mutually exclusive. Recent work on
budding yeast (Wang et al., 2014) favors a two step model. In the ﬁrst place, kinetochore
attachment may de-sensitize the SAC for activation (for example, by compromising Mad2
binding to kinetochores). After bipolar attachments, tension on sister kinetochores may
deﬁnitely silence the SAC and allow progression into late mitosis. It is still unclear whether
the proposed SAC silencing network is conserved and which proteins could represent the
respective counterpart in higher eukaryotes. More work will be needed to elucidate these
aspects and merge them with the previous ﬁndings.
1.2.2 Aneuploidy as a consequence of a deregulated mitotic check-
point
The direct progeny of checkpoint deﬁcient cells is usually viable, unless the formation of the
mitotic spindle is perturbed (such as in the presence of spindle poisons). In fact, chromosome
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Figure 1.3: Outline of the molecular players of the mitotic checkpoint. A) As long as the last
kinetochore is not properly attached to the mitotic spindle, the SAC is active and the Bub3/BubR1/Mad2
prevents Cdc20 binding to the APC/C complex, thus protecting cyclin B and securin from degradation. B)
When all kinetochores are attached to microtubules coming from opposite spindle poles, the checkpoint is
satisﬁed and APC/Cdc20 can target securin and cyclin B for ubiquitin (Ub) mediated degradation. Separase
can cleave cohesin protein complexes so that chromatids are free to segregate towards opposite spindle poles.
This allows metaphase to anaphase transition and further progression of the cell cycle.(Figure adapted from
(Geert et al., 2005)).
segregation may still take place even beyond perfection. Nevertheless, MC deﬁciency will
inexorably lead to increased aneuploidy and cell death over time.
If the SAC is chronically activated, instead, cells are blocked in mitosis for a range of
time that varies across diﬀerent species and diﬀerent cell types within the same organism.
However, cells are unable to keep the mitotic state for indeﬁnite time and, eventually, will
complete mitosis through molecular mechanisms that have not been fully understood yet.
Cells may adapt and exit mitosis through a mechanism known as mitotic slippage (Rieder
and Maiato, 2004), which seems to be a recurrent modality in diﬀerent species. The key
event is cyclin B degradation, which surprisingly happens even though the SAC has not
been satisﬁed. Upon mitosis completion, cells are invariably aneuploid (Brito and Rieder,
2006). What happens to this immediate progeny will depend on the degree of aneuploidy,
the amount of DNA damage that has been generated and on the cell type itself. For in-
stance, if the p53 pathway is active, the outcome may be represented by G1 arrest followed
by senescence or apoptosis. In contrast, cells lacking p53 could survive and further divide,
generating even more aneuploid daughter cells.
Cells facing a prolonged mitotic arrest may also be directed to a cell death path known
as mitotic catastrophe (Vakifahmetoglu et al., 2008). This term is used to describe an
atypical mechanism of death that senses mitotic failure and responds to it by driving the cell
into an irreversible state, be it apoptosis, necrosis or senescence (Vitale et al., 2011). It has
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Figure 1.4: Mechanisms leading to aneuploidy. The normal SAC events are shown in the center and
highlighted in blue. On the left: loss of the MC leads to cell death. Down-regulated MC favors premature
separation of sister chromatids and near-diploid aneuploidy. On the right: consequences of an over-active
checkpoint may be either cell death or lagging chromosomes which, thereafter, give rise to near diploid or
tetraploid cells. Outcomes similar to an over-active chekcpoint - such as cell death or lagging chromosomes
- are generated by multiple centrosomes. (Figure taken from (Schvartzman et al., 2010)).
been related to various morphological and biochemical changes; however, the precise mole-
cular players that regulate mitotic catastrophe have not been characterized yet. Incorrect
chromosome distribution in mitosis may compromise cellular function, reduce cellular ﬁtness
or, most importantly contribute to tumorigenesis. For these reasons, mitosis-incompetent
cells should be eliminated and mitotic catastrophe could be seen as an onco-suppressive
mechanism whose aim is to protect against genomic instability (Vitale et al., 2011).
1.3 Aneuploidy and CIN in human tumors
In this part, the relationship between aneuploidy and human tumors will be developed with
particular emphasis to deregulation of the mitotic checkpoint as CIN trigger. It is important
to mention that alteration of the SAC is not the only mechanism that can generate aneu-
ploidy in vivo. However, this has been reviewed elsewhere (Holland and Cleveland, 2012)
and is not the aim of this work.
Even normal cells can occasionally missegregate chromosomes in the presence of a fully
functional mitotic checkpoint (Hartwell and Smith, 1985). This generates aneuploidy, but
the consequences at organismal level are, usually, not harmful and cells with unbalanced
chromosome number are strictly controlled. In contrast, in human tumors many cells ac-
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quire CIN, a condition characterized by continuous gain and loss of chromosomes at every
mitotic event. A recent study showed that 68% of human solid tumors are aneuploid (Duijf
et al., 2012). CIN is the characteristic of many aneuploid cancer cells, and the source of con-
stantly evolving karyotypes and tumor heterogeneity. This phenomenon has been associated
with resistance to therapy and poor patient prognosis (Kuukasjarvi et al., 1997; Gao et al.,
2007; Choi et al., 2009; McClelland et al., 2009; Heilig et al., 2010).
It is fundamental to highlight that aneuploidy and CIN are not synonyms. In fact, an-
euploidy describes a state of non-euploid chromosome content, while CIN deﬁnes a rate of
karyotypic change. Consequently, while CIN cells can be deﬁned aneuploid as well, this
correlation is not bidirectional and some tumors may be stably aneuploid without the ac-
quisition of further karyotypic changes.
As point of nomenclature, W-CIN (whole chromosome instability) is a condition deﬁned by
gain or loss of entire chromosomes and results in numerical chromosomal abnormalities. On
top of this, in cancer cells rearrangements in chromosome structure, such as translocations,
deletions, inversions or ampliﬁcations, can also be observed and this condition is known as
S-CIN (segmental chromosome instability (Geigl et al., 2008; Ricke et al., 2008)).
1.3.1 Over-activation of the SAC promotes CIN in human tumors
As mentioned in 1.2.2, deregulation of the mitotic checkpoint leads to aneuploidy. Theo-
retically, mitotic errors can be generated both via down regulation or overactivation of the
SAC machinery. Nevertheless, it is important to identify the real events that could promote
tumor formation in vivo and which ones are to be found in human patients.
Since complete abrogation of the mitotic checkpoint is lethal, a weakened SAC is the only
status to be considered as CIN source. One could predict that in this condition, the SAC
could be satisﬁed at a lower threshold, thereby generating W-CIN as a consequence of prema-
ture separation of sister chromatids. Indeed, this hypothesis has been conﬁrmed in several
mouse models bearing conditional or hypomorphic mutations in mitotic checkpoint genes
(Kalitsis 2000; Michel et al., 2001; Babu et al., 2003). High aneuploidy is a characteristic
of both mouse embryonic ﬁbroblasts and tissues; several of these models (i.e. Bub1 hypo-
morphic mice and Mad1, Mad2 and Cenp-E heterozygous mice) show an increase in tumor
susceptibility.
However, these results have found direct evidence in humans only in sporadic cases. As
a matter of fact, extensive analysis of human aneuploid tumors (Perez de Castro et al.,
2007) have pointed out that mitotic genes are rarely mutated in human cancers. Down-
regulation of the SAC is also extremely rare.
So far, mosaic variegated aneuploidy is the only genetic disorder associated with mitotic
checkpoint functions and compatible with complete embryonic development, that has been
discovered. Mosaic variegated aneuploidy (MVA; OMIM 257300) is a rare autosomal re-
cessive disorder, caused by germline mutations in the checkpoint protein BubR1 or the
centrosomal protein CEP57 (Snape et al., 2011). MVA patients have severe aneuploidy and
therefore, this proves that defects in the SAC machinery can cause aneuploidy in humans.
These patients are characterized by an extremely severe phenotype and the absence of other
related syndromes reinforces the hypothesis that loss/inactivation of the mitotic checkpoint
is not an event likely to happen in humans. This underlines, again, the concept that the MC
is an essential pathway in mammals.
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The most convincing evidence against mitotic gene downregulation in human cancers is
given by the expression proﬁle analysis of aneuploid tumors (Rhodes et al., 2004; Rhodes et
al., 2007). Carter et al. (Carter et al., 2006) extrapolated a chromosome instability signa-
ture (CIN 70 from the 70 highest scoring genes) from expression proﬁles of genes that were
consistently correlated with total aneuploidy in six diﬀerent cancer types. In particular, the
CIN 70 signature predicted and stratiﬁed breast cancer patients with histological grade 1 and
grade 2 lesions according to clinical outcome. Cells with high aneuploidy levels and the CIN
70 signature may correlate for three reasons. First, cells with aneuploid DNA complement
may need to synthesize higher levels of proteins involved in the mitotic checkpoint as well
as in DNA duplication. Second, if the SAC machinery was impaired (a condition which has
been discussed as scarcely possible in this chapter), aneuploid cells may need to produce
more of its components as a natural compensatory mechanism. Third, over-expression of
CIN genes may allow completion of mitosis in the presence of functional checkpoints, result-
ing in higher proliferative advantage and possibility to fuel tumor heterogeneity.
Many of the mitotic genes associated with CIN are periodically expressed during the cell
cycle, under the control of the E2F transcription factor (Ren, 2002). As a consequence, also
an impaired Rb pathway may alter their expression (Schvartzman et al., 2011). Given this,
it could have been possible that the prognostic ability of the CIN 70 signature proposed
by Carter et al., was due to the detection of the proliferation rate rather than CIN itself.
However, gene sets representing the mitotic spindle assembly and spindle checkpoint highly
correlated with the CIN signature and their scores were signiﬁcantly higher if compared to
the cell cycle genes. This is consistent with the hypothesis that the CIN70 signature is indeed
a prognostic marker and not a simple reﬂection of an increased mitotic rate.
As piece of evidence from mouse models, Mad2 and Hec1 conditional overexpression (Diaz-
Rodríguez et al., 2008; Sotillo et al., 2007) has been shown to be suﬃcient for generating
aneuploidy and initiating tumor formation. Both models are predicted to generate mitotic
arrest and, consequently, W-CIN. Moreover, Mad2 overexpression has been to shown to lead
not only to W-CIN but also to double strand breaks, deletions and ampliﬁcations (Sotillo
et al., 2007). In these mice, continuous Mad2 over-expression was not required for tumor
maintenance, suggesting that once a karyotype has been selected, it can be stably maintained
in the absence of CIN if it confers an advantage for malignant progression.
As brieﬂy mentioned before, a recent work showed that Mad2 over-expression is the mediator
of CIN upon inhibition of the Rb and p53 pathways (Schvartzman et al., 2011), which are
the two most commonly deregulated pathways in cancer. Mad2 expression is controlled
by the E2F transcription factors and loss of Rb or p53 leads to its over-expression. Thus,
over-activation of the SAC machinery may be directly caused by deregulation of one of its
components as well as through abnormalities in upstream connected pathways.
Work on human cell lines provides an explanation for Mad2 induced CIN (Kabeche and
Compton, 2012). This paper unravels a new role for the Mad2 protein, which is independent
of its function in the SAC machinery because it does not rely on Mad1 mediated recruit-
ment to the kinetochores (see 1.2.1). When Mad2 is over-expressed, kinetochore-microtubule
attachments are hyperstabilized and, therefore, the possibility of correction of merotelic at-
tachments is strongly impaired.
Among other known regulators of kinetochore-microtubule attachments, Aurora B seems to
be aﬀected by Mad2 over-expression. The amount of Aurora B at centromeres is reduced
and its functional activity is also aﬀected. In fact, kinetochore-microtubule attachments are
destabilized by Aurora B action. Thereby, Mad2 over-expression indirectly acts on Aurora
B to attenuate the degree of kinetochore-microtule destabilization. As consequence, the rate
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of lagging chromosomes and CIN are greatly increased.
Thus, data from cell lines, mouse models and, most importantly, human samples have pro-
vided evidence that over-activation of the SAC is a common phenomenon in human tumors
and can be causative of CIN in vivo. Therefore, MC over-activation, rather than downregu-
lation, might be the primary cause of aneuploidy and CIN in patients.
1.3.2 The aneuploidy paradox
Since aneuploidy is frequently observed in human tumors, this notion has been used to hy-
pothesize a possible role of CIN in tumorigenesis. However, several lines of evidence have
demonstrated that aneuploidy has a clear antiproliferative eﬀect and the debate on its tumor
promoting or tumor suppressor function is still open (Holland and Cleveland, 2009).
As already mentioned, aneuploidy is detrimental, or even lethal, during development. In
humans, germline aneuploidy is a considerable barrier towards complete embryo formation
and, in adults, is the leading cause of mental retardation (Hassold et al., 2007; Brown S.,
2008). All human autosomal monosomies are lethal and only autosomal trisomies of chro-
mosomes 13, 18 or 21 are viable. Only trisomy 21 (Down's syndrome, OMIM 190695) is
compatible with life until adulthood. Aneuploidies of human sex chromosomes are much
better tolerated and, for instance, Klinefelter's syndrome (47, XXY; OMIM 400045) is the
most common known aneuploidy after trisomy 21. Development up to puberty is usually
normal, however fertility and cognitive capacities may be impaired in adulthood, even though
there is high phenotypic variability among patients bearing the same karyotype.
Several groups have focused on the correlation between aneuploidy and cellular growth in
vitro. These studies proved that, in this context, chromosome imbalances are detrimental
and results are consistent both in S. cerevisiae and M. musculus (see 1.3.3).
Under normal growth conditions, yeast strains with supernumerary chromosomes (Torres et
al., 2007; Pavelka et al., 2010) or trisomic MEFs cell lines have impaired growth rates and
altered metabolism. At least in S. cerevisiae, aneuploidy detrimental eﬀect is not due to the
increase of DNA content per se (Torres et al., 2007), but it correlates to the number of genes
encoded by the exogenous amount of DNA (Torres et al., 2007; Williams et al., 2008). The
forced production of unnecessary proteins could cause an inhibitory eﬀect, called proteotoxic
stress, whose ultimate readout is impaired cellular growth in vitro. This observation could
also explain why aneuploidy leads to higher sensitivity in response to drugs that target pro-
tein synthesis, folding and degradation (Tang et al., 2011). However, studies on aneuploid
human tumors showed that extra chromosomes do not preferentially have a low gene copy
number, suggesting that, at least in long term tumorigenesis, proteotoxic-mediated growth
impairment does not constitute a barrier in vivo (Duijf et al., 2012). Thus, in vitro data do
not recapitulated what is observed in human tumors.
Then, if 68% of human solid tumors are aneuploid (Duijf et al., 2012), how does this infor-
mation correlate with aneuploidy as being detrimental to cellular growth and ﬁtness?
One should consider that in vitro experiments are carried out in the absence of environmen-
tal selective pressure (i.e. nutrients, oxygen, growth factors etc.), thus, clones are selected
for the fastest doubling time. Conversely, tumor cells must acquire the ability of constant
growth in changing intracellular and extracellular environments. Therefore, tumors might
trade a reduced proliferation rate for an increased capacity to adapt and evolve. Intere-
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stingly, a slow proliferation rate in human colorectal cancers has been linked to increased
tumor aggressiveness and ability to metastasize (Anjomshoaa et al., 2009), and aneuploidy
is linked to poor patient outcome in those cancers (Araujo S.E., 2007).
For instance, aneuploid yeast strains proliferated signiﬁcantly better, if compared to eu-
ploid counterparts, under severe genetic or environmental pressures (Pavelka et al., 2010).
Furthermore, the emergence of drug resistance is also promoted by CIN in the presence of
selective stress conditions (Chen et al., 2012).
This highlights the fact that aneuploidy has not only one possible outcome. Even if CIN
may be detrimental for cellular ﬁtness, its impact seems to depend mostly on the particular
karyotype and the environmental conditions. As a matter of fact, somatic aneuploidy seems
to be well tolerated in many contexts in vivo (Babu et al., 2003; Jeganathan et al., 2007;
Michel et al., 2001; Weaver et al., 2007). Tumors must cope with constantly changing en-
vironments; therefore selection for speciﬁc aneuploid karyotypes could confer an advantage
during the tumorigenesis process and represent a worthy trade oﬀ in the long run.
1.3.3 Aneuploidy can act both as a tumor suppressive and a tumor
promoting event
If aneuploidy consequences are context-dependent, then two diﬀerent, not mutually exclu-
sive, outcomes are envisaged: tumor suppressive and tumor promoting. Down syndrome
patients are one of the most outstanding exempliﬁcation of this concept, since they have a
reduced rate of solid tumors opposed to a signiﬁcant increase in hematological malignancies
(Satgé et al., 1998; Hasle et al., 2000; Yang et al., 2002).
Mouse models served as conﬁrmation of this context-dependent aneuploidy phenomenon.
For instance, aneuploid CENP-E heterozygous mice showed an increase in lung tumors and
spontaneous lymphomas, but had decreased incidence of carcinogen-induced tumors and,
when crossed with p19ARF knockout mice, had longer tumor-free survival (Weaver et al.,
2007). Crossing of haploinsuﬃcient Bub1 mice into diﬀerent genetic backgrounds had, again,
opposite outcomes: when in combination with p53+/- or APCMin/+ mice tumorigenesis was
favored, but it was suppressed if together with PTEN heterozygosity (Baker et al., 2009).
Interestingly, haploinsuﬃciency of BubR1 within the same model decreased the rate of small
intestinal tumors and at the same time promoted colon tumorigenesis in the APCMin/+ mouse
model (Rao et al., 2005).
One explanation for these observations is that diﬀerent levels of aneuploidy are uniquely
dealt with in speciﬁc tissues and environments. Low aneuploid levels may still be compa-
tible with cell viability and, in particular karyotypic combinations, promote tumorigenesis.
In contrast higher levels may promote cell death and reduce tumor incidence. This concept
has been recently demonstrated from the Weaver lab (Silk et al., 2013). Mice heterozygous
for the CENP-E protein were crossed into diﬀerent genetic backgrounds: ARF-/-, Mad2+/-
and INK4a-/-. Both ARF-/- and Mad2+/- mice were characterized by mild missegregation
rates and low CIN. The combined reduction of CENP-E caused higher rates of abnormal
mitotic ﬁgures, cell death and decreased tumor incidence. In contrast, when in the INK4a
null background, CENP-E heterozigosity did not suppress tumor formation. This contrast
ﬁnding can be explained considering that INK4a tumor controls the G1-S transition of the
cell cycle and is not directly involved in aneuploidy prevention. Therefore, CENP-E pro-
tects mice from tumor formation only when acting in concert with an already pre-existing
mild level of CIN: the induction of higher levels of aneuploidy induce cell death thereby
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increasing animal lifespan. This ﬁnding is of extreme interest, since increasing chromosome
missegregation rates in already unstable aneuploid tumors could be considered as a valuable
therapeutic strategy.
Consistent with this view, intermediate levels of CIN have been associated with a poor out-
come in ER-negative human breast cancer, whereas high levels of CIN are correlated with
improved patient long-term survival (Birkbak et al., 2011; Roylance et al., 2011).
Loss of heterozygosity is another event promoted by CIN that may help malignant transfor-
mation. This is of particular relevance in a tumorigenic context if main tumor suppressor
genes are represented only by one functional copy. Again proof for this phenomenon comes
from in vivo studies on mouse models (Baker et al., 2009). BubR1 insuﬃciency - which
enhances chromosome missegregation - promotes loss of heterozigosity of the wildtype allele
if crossed in the p53+/− or APCMin/+ backgrounds. In the ﬁrst case, mice are predisposed
to the formation of thymic lymphomas, while colon tumors arising in the APCMin/+ models,
instead, consistently gained the mutant copy of the allele at the expenses of the wildtype one.
As recently reviewed (Janssen and Medema, 2012), mouse models that combine numerical
CIN and human relevant oncogenes in breast cancer are still scarce. This, despite evidences
of the high incidence of CIN in human tumors and the fact that oncogene dependent mouse
models often result in karyotipically stable tumors - a situation that does not reﬂect the
human disease. Recently, three mouse models of numerical CIN have been published, all
from the Van Deursen lab (Baker al., 2012; Nam and van Deursen, 2014). In case of BubR1
over-expression, mice were protected against aneuploidy, ageing and had reduced tumor
formation even when crossed in a Ras oncogenic background. BubR1 over-expression was
hypothesized to increase ﬁdelity of chromosome segregation in mitosis, thereby acting as
a protective mechanism against the generation of aneuploid cells. This demonstrates that
missegregation errors in mitosis can greatly increase tumor incidence and, if chromosome
segregation accuracy is increased, the SAC could be exploited in a preventive manner. The
other two models were generated to unravel the role of cyclin B1 and B2 in cancer. An-
euploidy is a characteristic of both transgenic animals and, even though generated through
diﬀerent mechanisms, determines an increase in spontaneous and carcinogen induced tumors.
CIN has been recognized to play a fundamental role in determining the response to anticancer
therapies in primary tumors and, after, in tumor relapse. In mice, combined over-expression
of Mad2 and KrasG12D promoted primary tumorigenis but did not aﬀect the regression of
Kras driven lung carcinomas. However, tumors that experienced Mad2-driven CIN relapsed
with a 50% higher frequency after the removal of the Kras oncogene, suggesting that the
genetic instability imparted by CIN facilitated the evolution of resistant karyotypes (Sotillo
et al., 2010).
These observations support the view that the eﬀect of aneuploidy on tumor development
is dependent on, at least, three factors: a speciﬁc abnormal karyotype, the particular genetic
background and the tissue microenvironment. Of course, we cannot rule out the possibility
that more factors could inﬂuence aneuploidy outcome. For this reason, CIN mouse models
provide an extremely valuable tool to study these variables and, when possible, test the
eﬃcacy and resistance to current and potential drugs.
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1.4 Human breast cancer and CIN
1.4.1 Breast cancer
Worldwide breast cancer is the second leading cause of cancer-related death in women,
topped only by lung cancer. It is estimated to account for 28% of new cancer diagnosis in
women. The American Cancer Society estimates that, in 2014, about 295,000 women will
be diagnosed with breast cancer and about 40,000 will die of it.
Even though breast cancer treatment and, above all, early diagnosis has majorly advanced
since the past decade, this disease is still characterized by unresolved scientiﬁc and clinical
problems. These are related to prevention, diagnosis, tumor progression, treatment, recur-
rence and therapeutic resistance.
Trying to shed light onto these aspects is challenging, since breast cancer is not a single
disease, but is highly heterogeneous both at the molecular and, consequently, clinical level.
Gene expression proﬁling of tumor sets have revealed ﬁve major molecular subtypes of breast
cancer: basal-like, luminal, normal breast-like, Her2 positive and triple negative (Her2, ER,
PR negative). Molecular diﬀerences underline heterogeneous clinical pathologies and some
of them can be used to delineate therapeutic approaches.
1.4.1.1 Breast cancer aetiology
Mammary glands are tubulo-alveolar glands, probably derived from modiﬁed apocrine sweat
glands. 15 to 20 lobes of branched glands constitute the adult mammary gland. The lacti-
ferous duct branches into further smaller ducts, at the end of which alveolar lobules with
secretory cells can be found. Epithelial mammary gland cells are lined by a second layer
of myoepithelial cells and surrounded by adipose and connective tissue and extracellular
matrix. Mammary glands are responsive to hormone signaling (estrogen and progesterone),
therefore their activity is regulated by the endocrine system.
Figure 1.5: Schematic representation of the
mammary gland. The basic components of a
mature mammary gland are the alveoli (hollow
cavities, a few millimeters large) lined with milk-
secreting cells and surrounded by myoepithelial cells.
These alveoli join to form groups known as lobu-
les. Each lobule has a lactiferous duct that drains
into openings in the nipple. Figure taken from
http://nongae.gsnu.ac.kr/ cspark/teaching/chap10.
html.
As other types of cancers, breast tumors are thought to evolve over long periods of time.
Epithelial cells responsible for the transformed state are located in terminal duct lobular
units (Welling-Jensen model) and progressively acquire distinct morphological and molecu-
lar changes. Evolution of the neoplastic disease starts from hyperplasia, then progresses to
atypical hyperplasia, in situ carcinoma, invasive carcinomas and, ultimately, metastasis. In-
creased epithelial growth characterizes initial hyperplasias, and later stages can be identiﬁed
by loss of cell adhesion and polarity. Further growth and histological heterogeneity marks
the entry into in situ carcinoma stage, a condition that might be accelerated by genomic
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instability. Invasion of the extracellular matrix and surrounding stroma is the prerequisite
for spread of the disease to other organs. Breast tumors primarily metastasize to the brain
and to the bone, in addition to the lung, usually via the lymphatic system.
At the molecular level, most changes driving breast cancer tumorigenesis fall into two well
known categories: gain of function mutations in proto-oncogenes, which are involved in cell
growth, division and survival; and loss of function mutations in tumor suppressor genes that
normally help prevent uncontrolled cellular growth and promote DNA repair and cell cycle
activation (see table 1.1).
Family history and hereditary factors are one of the strongest determinants of risk for breast
cancer development. For instance, germline mutations of the BRCA1 and BRCA2 genes ac-
count for about 90% of all familial cases and the tumor suppressor p53 is also accounting for
a high risk in genealogical trees. Yet, only 5-10% of all newly diagnosed breast carcinomas
are linked to genetic factors while the remaining ones are sporadic. Table 1.1 illustrates the
most common oncogenes and tumor suppressor genes found in breast cancer. Herein, I will
focus speciﬁcally on two oncogenes - Her2 and c-MYC - which will be relevant for the work
of this dissertation.
Intra-tumor heterogeneity is a widely demonstrated characteristic of human malignancies,
which encompasses genetic, epigenetic and karyotypic levels. Despite this, cells that became
malignant because of oncogenic driven mutations/over-expression, still rely on the sustained
expression of their initial oncogenic lesion for survival, a phenomenon known as oncogene
dependence (Weinstein et al., 2008). Supporting evidence has been obtained from cancer
cell lines, genetically engineered mouse models and clinical trials involving speciﬁc molecular
targeted agents. In fact, the concept of oncogene dependence has provided the rationale
for modern targeted therapy, whose aim is to provide eﬃcient and safe cancer treatment.
However, current therapeutic treatments are only partially successful and cannot completely
eradicate the disease. Cancer cells may display primary resistance, if intrinsic factors are
limiting drug eﬀect, or secondary resistance if tumors adapt over time to the main drug
target or over-ride its eﬃcacy through diﬀerent pathways. From the clinical point of view,
this means that patients are faced, over time, with relapses that do not longer respond to
the initial treatment.
 The c-MYC oncogene
The c-MYC oncogene encodes a transcription factor with pleiotropic functions, involved in
cellular proliferation, diﬀerentiation and apoptosis. It is over-expressed or ampliﬁed in a
relevant part of human breast tumors (15-25%, (Nass S.J., 1997)) and can be associated
with more aggressive clinical outcome and worse prognosis. De-regulation in c-MYC ex-
pression determinates excessive activation of its downstream pathways, thus leading fertile
soil for tumor formation. It is still not clear whether aberrant c-MYC expression alone is
suﬃcient to cause breast tumorigenesis in humans (albeit being proved in mice (D'Cruz et
al., 2001)), however its over-expression is clearly associated with breast cancer (Nass S.J.,
1997). Interestingly enough for the topic of this dissertation, DNA damage and karyotypic
abnormalities may be associated with aberrant c-MYC expression. One critical function
of this oncogene, which greatly facilitates the emergence of genome instability, is apoptosis
activation. If this response is active, then karyotypically abnormal cells will, most likely, be
eliminated. In contrast, if this pathway is not functional, genome destabiliazation can be
generated at diﬀerent levels. For instance, c-MYC deregulation increases metabolic activity
and, consequently ROS production. This may generate DNA damage through oxidation and
potentially induce rearrangements if DNA breaks are not repaired (Vafa et al., 2002).
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Oncogenes Incidence Cellular function
Her2
Ampliﬁcation in 20-30%,
somatic mutations 1.6%
Cell survival,
proliferation and growth
c-MYC
Ampliﬁcation and
over-expression 15-25%
Cellular proliferation,
diﬀerentiation, apoptosis
Cyclin D1
Ampliﬁcation 10-20%,
over-expression 40-50%
Cell cycle progression
G1-S phase
Cyclin E
Ampliﬁcation 2%,
over-expression 20-30%
Cell cycle progression
G1-S phase
Tumor suppressors
p53 Mutation 20-30%
Cell division, DNA
repair, apoptosis
p27 and Skp2 Mutation 1%
Negative regulators of
the cell cycle
BRCA1
Mutation 90% familial
cases
DNA repair pathway
Table 1.1: Oncogenes, tumor suppressor genes and relative incidence in human breast cancer.
c-MYC also plays a role in the regulation of G1/S and G2/M cell cycle checkpoints, and
deregulated expression can lead to aberrant DNA replication, which, in turn, causes ge-
nomic instability (Santoni-Rugiu et al., 2000; Spruck et al., 1999). Because of the central
role of c-MYC in many cellular functions and in every cell, this oncogene is currently not
druggable in the clinics and targeted therapy against it does not exist.
 The Her2 (human epidermal receptor 2) oncogene
The Her2 protein is encoded by the ErbB2 gene and belongs to the EGFR (epidermal
growth factor receptor) tyrosine/kinase transmembrane receptor family. Four functionally
and structurally related members are part of it: EGFR (alternatively named Her1, ErbB1),
Her2 (or c-ErbB2; in rodents, Neu), Her3 (alias ErbB3) and Her4 (ErbB4). All of them
share a conserved extracellular, ligand binding domain, a transmembrane portion and a
cytosolic ATP-binding kinase domain. Extracellular ligand binding leads to receptor acti-
vation and conformational changes. Activation relies on dimerization with another protein
family member (heterodimerization) or with the same partner (homodimerization). Her2
is known as the deaf member of the family, since the lack of ligand domain makes its
activation strictly dependent on heterodimerization. Homodimerization of Her2 with itself
does happen, however only when expressed at very high levels or in the presence of muta-
tions in the transmembrane domain. Receptor activation results in trans-phosphorylation of
their intracellular domain and the possibility of interacting with cytosolic signaling molecules
and other membrane signaling pathways (Montemurro and Scaltriti, 2014). These are the
Ras/Raf mitogen activated protein kinase, the PI3K/Akt and the PLC/PKC pathways.
In the family, the mute Her3 member lacks tyrosine kinase activity; therefore, as Her2,
it must heterodimerize with other partners. Even though all heterodimer combinations are
possible, the Her2/Her3 one is considered the most powerful in terms of oncogenic potential
(Pinkas-Kramarski et al., 1996; Alimandi M, 1995).
As a proto-oncogene, Her2 is expressed at low physiological levels on the surface of epi-
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thelial cells and is essential for the correct development of the mammary gland (Browne
B.C., 2009). Interestingly, benign breast disorders are rarely characterized by Her2 over-
expression (Allred et al., 1992; Mansour E.G., 1994), which usually takes place at later
stages. However, 20-30% of malignant breast tumors are characterized by ampliﬁcation or
over-expression of Her2, delineating a speciﬁc subtype of disorders deﬁned as Her2 positive
(Slamon et al., 1987). Historically, Her2+ breast tumors have had one of the worst pro-
gnosis, which correlated with low disease-free and overall survival rates (Paik et al., 2000)
compared to Her2 negative ones (Slamon et al., 1987; Seshadri et al., 1993). This is why
there has been intense research towards the development of potential targeted therapy drugs
against over-expressed Her2 receptor (Yarden and Pines, 2012). First convincing results
came from animal studies performed by Greene and Weinberg groups. Fibroblasts ectopi-
cally expressing an oncogenic form of rat Her2 acquired the capacity of growing tumors in
host animals. This condition was completely eliminated if a Her2 targeted antibody was
administered (Drebin et al., 1985). Shortly after (Hudziak et al., 1989), Genetech developed
another murine antibody, 4D5, which speciﬁcally inhibited the growth of Her2+ cell lines
derived from human breast tumors. 4D5 was the predecessor of trastuzumab (Carter et al.,
1992; Vu and Claret, 2012), the monoclonal antibody approved in 1998 by the FDA (Food
and Drug administration) for the treatment of Her2-metastatic breast cancer. Later, in
2006, it received the second approval for adjuvant treatment of Her2 positive breast cancer.
Trastuzumab is one of the most important innovation in the management of breast cancer
seen in the last decades, as it reverted the natural outcome of Her2 positive tumors trans-
lating the concept of aggressive subtype to the one of improved prognosis. As a matter of
fact, cost-eﬀectiveness of trastuzumab regimens has been demonstrated both in combination
with adjuvant therapies and in the metastatic settings (Garrison et al., 2007; Liberato et al.,
2007; Lidgren et al., 2008). Women with Her2+ breast cancer, treated with trastuzumab,
have 44% reduction in risk of death compared to women with Her2 negative disease in
primary line treatment. Moreover, by 5 years relapse follow up, survival outcomes are simi-
lar in Her2 positive, trastuzumab treated, and Her2 negative patients (Liberato et al., 2007).
Nevertheless, due to either intrinsic or acquired mechanisms of resistance, the median du-
ration of response is modest (Gajria and Chandarlapaty, 2011; Zhang et al., 2011). Un-
fortunately, less than 35% of Her2+ patients initially respond to trastuzumab, which means
that these patients are inherently resistant to the drug. On the other hand, around 70% of
patients who initially responded experience progression to metastatic disease within a year
(Gajria and Chandarlapaty, 2011), proving the emergence of acquired resistance. So far,
three main mechanisms of acquired resistance have been discovered: structural mutations of
the Her2 receptor (Christianson et al., 1998), over-expression of other EGFR family mem-
bers (Garner et al., 2013) and deregulation of expression of downstream components of the
Her2 pathway (Berns et al., 2007).
In order to identify gene expression signatures speciﬁc for resistance and predict therapy
ineﬀectiveness, proﬁling of Her2+, trastuzumab treated specimen has extensively been con-
ducted (Khoury et al., 2010; Shiu et al., 2014). These screenings have pointed out the
existence of gene sets diﬀerentially expressed in Her2+, trastuzumab treated patients ver-
sus Her2+ patients that did not receive trastuzumab. In particular, only a fraction of
trastuzumab resistant patients remains truly addicted to the ErbB2 oncogene, developing
further dependencies (such as the one for the TFAP2C transcription factor) that might be
exploited in the clinical setting (Shiu et al., 2014).
One of the reasons why we still heavily rely on gene expression proﬁling is that we still
do not know the exact mechanism of action of trastuzumab and, therefore, the reason for
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emergence of resistance to it. To overcome trastuzumab resistance in patients, new drugs
against trastuzumab resistant cancers have been developed (Mohamed et al., 2013), leading
to alternative strategies in the management of this disease. Even though new drugs can help
improving patients overall survival, there is an extreme need to understand the molecular
mechanisms underlying acquired resistance to therapy, so that new avenues could be opened
in the treatment of the disease.
1.4.2 CIN in breast cancer
Breast tumors appear to be characterized by genome instability even at early disease stages,
when tissues still look normal from a histological point of view. As previously mentioned,
inherited breast cancer germline mutations - for instance, in BRCA genes - are involved in
DNA repair and are, therefore, directly connected to the maintenance of genome integrity.
Genome instability, whether inherited or not, results in a greater potential to select for
genetic changes (such as gene loss, gene ampliﬁcation, point mutations and chromosomal
aberrations) that would confer an advantage in proliferation, cell survival and drug resi-
stance. Interestingly, loss of heterozygosity and changes in gene copy number seem to be
correlated with the transition between hyperplasia and ductal carcinoma in situ, thus favor-
ing higher grades of the disease.
In breast cancer, CIN scores are signiﬁcantly associated with prognosis (Smid et al., 2010) -
measured by the time to distant metastasis - and progression in ER+, luminal B and Her2+
subtypes. In contrast, within ER- samples, CIN is likely related to the onset but other
factors appear to inﬂuence the progression of the disease. As previously mentioned, Carter
et al. (Carter et al., 2006), were able to identify an expression signature of 70 genes corre-
lating with CIN that predicts poor prognosis in diﬀerent types of cancers, including breast.
Further reﬁnements of this gene list (Szasz et al., 2013) have proven useful to stratify breast
cancer outcome in a speciﬁc subset of specimen, further reinforcing the importance of CIN
in poor prognosis. In fact, CIN was demonstrated to be an independent variable associated
with improved long term survival in ER- breast cancer patients, while it appears to be asso-
ciated with higher risk of death in ER+ patients (Birkbak et al., 2011; Roylance et al., 2011).
As reviewed by Perez de Castro et al. (Perez de Castro et al., 2007) alterations of genes
involved in spindle formation or chromosome segregation are frequent in diﬀerent types of
cancers and represent a direct cause for chromosome instability. These genes are rarely found
mutated in human tumors, but one should not forget that also minor expression changes,
still compatible with cell viability, might be suﬃcient to deregulate the mitotic checkpoint
and induce genome instability.
Regarding Mad2, only rare mutations have been found in bladder, lung and breast cancer
(Gemma et al., 2001; Perez de Castro et al., 2007). As reported in the ONCOMINE database
(http://www.oncomine.org) (Rhodes et al., 2004), Mad2 is signiﬁcantly up-regulated in a
subset of human cancers, including breast. Further assessment of Mad2 expression from
patient specimen has reinforced this notion and linked Mad2 to invasive ductal breast carci-
nomas (Scintu et al., 2007; Borowsky, 2011).
Mad2 has been long known as an E2F target gene (Hernando et al., 2004) and also deregul-
ation in the p53 axis may alter Mad2 expression. In fact, the p21 kinase is a direct target of
p53, and its role is to maintain an hyper-phosphorylated Rb protein preventing unscheduled
activation of the E2F transcription factors (Polager and Ginsberg, 2009). Therefore, p53 is
also involved in controlling the correct cell cycle timing via indirect regulation of the Rb pro-
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tein. This is of tremendous relevance, since deregulation in either Rb/E2F or p53 pathways
may lead to Mad2 deregulation, thus fueling CIN and tumor heterogeneity. As a matter
of fact, recently published results clearly show that Mad2 over-expression is a consequence
of impaired Rb or p53 mutant background and, in this context, represents the principal
mediator of CIN (Schvartzman et al., 2011).
Therefore, in order to mimic the unstable aneuploidy seen in human tumors, we decided
to use a mouse model that conditionally over-expresses the Mad2 protein (Sotillo et al.,
2007). In this way, we can induce genomic instability and study tumorigenesis in an im-
proved mouse model of breast cancer.
1.4.3 Modeling of the human disease
As for other types of cancer, it is not possible to generate a perfect model, since tumors -
and breast malignancies as well - are constituted by an array of diﬀerent diseases. The ﬁrst
and simplest surrogate to study breast cancer is represented by cell culture lines. However,
the major drawback is the culture condition itself: these cells grow in 2D onto plastic dishes
that have nothing in common with the extracellular tumor environment.
Propagation of human tumor derived cell lines into immuno-compromised host mice is, for
sure, a great implementation compared to cell line culture. Nevertheless, it is important to
consider that, despite the use of a living organism, xenograft techniques do not allow the
study of the immune response, as well as the creation of a permissive microenvironment
related to pre-malignant stages. This is why genetically modiﬁed mouse (GEM) models
have played a pivotal role in the study of tumor diseases since the past century (Allred and
Medina, 2008; Borowsky, 2011; Cardiﬀ and Kenney, 2011). They have represented a great
advantage towards the generation of models that would encompass both biological comple-
xity at organismal level and human related driving mutations in cancer.
As far as breast cancer is concerned, mouse models have had enormous success for seve-
ral reasons. First of all, mouse mammary gland biology has been studied for many years
and it closely resembles the human one in many aspects, starting from development, tissue
architecture, to hormonal regulation and function. In second place, a lot of eﬀort was put
into the creation and generation of mammary gland speciﬁc promoters, such as the mouse
mammary tumor virus long terminal repeat (MMTV-LTR) the way acidic protein (WAP)
and beta lactoglobin (BLH). All these promoters are able to drive high transgenic expres-
sion speciﬁcally in mammary epithelial cells, allowing the design of elegant tissue speciﬁc
experiments. Last, since the mammary gland is a non essential organ - unless lactation is
desired - it is amenable to transplantation experiments (Daniel et al., 2014).
Apart from basic biology features regarding mammary gland biology, one relevant question
rising in the ﬁeld was related to the pathology of breast tumors in mice compared to human
specimen. Therefore, in 1999 a meeting of human and mouse breast cancer pathologists (NIH
Breast Cancer Think Tank and Annapolis Pathology Panel) developed a consensus report
comparing the pathology of 39 GEM and human breast cancers (Cardiﬀ et al., 2000). The
major conclusion of this meeting was that spontaneous breast carcinomas arising in mice did
not resemble any common type of human breast cancer. However, whenever tumorigenesis
was driven by speciﬁc transgenes, such as MYC, ErbB2 and Ras, tumors were characterized
by unique histologies, hardly distinguishable from the human counterpart. Hence, these re-
sults were considered as most signiﬁcant, highlighting the fact that driving oncogenic lesions
profoundly aﬀect tumor pathology both in humans and in mice.
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In humans, oncogenes usually drive tumor formation thanks to increased expression, which
can be due to deregulated expression or copy number variation. Therefore, the use of highly
active promoters in mice provides a valid surrogate to mimic this disease at the molecular
level. Further improvements were brought by the use of tetracycline inducible promoter
sequences (adopting a mammary speciﬁc promoter to drive the tet transactivator and a
second tet responsive driven element) and the administration of tetracycline/doxycycline as
major rate limiter (Gunther et al., 2002). The speciﬁcity and temporal control of transgenes
expression of this system has proved critical to a large variety of studies. In case of the
Her2 and MYC oncogenes, many tetracycline inducible mouse models have already been
generated and have been reviewed elsewhere (Borowsky, 2011).
As relevant for this dissertation and given the importance of the Mad2 protein in human
cancers, few mouse models have started giving insight into the biology of CIN tumors fo-
cusing speciﬁcally on this protein. Sotillo et al. (Sotillo et al., 2007) generated a mouse
carrying an inducible HA tagged Mad2 cDNA, under the control of the tetracycline sy-
stem. In MEFs, Mad2 over-expression was suﬃcient to transiently increase the number of
mitotic cells, which would eventually slip through becoming binucleated or mononucleated
with abnormal chromosome content. Mad2 over-expression was also causative of chromo-
some instability in vitro and, in vivo, able to initiate tumorigenesis in a wide spectrum of
tissues. Moreover, unlike oncogenes, continued over-expression of Mad2 was not required for
tumor maintenance. These results demonstrated for the ﬁrst time, that transient Mad2 over-
expression and chromosome instability could be an important stimulus in the initiation and
progression of diﬀerent cancer subtypes. Few years later, the ﬁrst mouse model combining
Mad2 over-expression with a lung tumor relevant oncogene (KrasG12D) was published (Sotillo
et al., 2010). They showed that induction of chromosome instability by over-expression of
Mad2 did not aﬀect the regression of KrasG12D-driven lung tumors when targeted therapy
was mimicked. However, tumors that experience transient Mad2 over-expression recurred at
elevated rates, compared to KrasG12D only induced malignancies. Thus, early chromosomal
instability may be responsible for tumor relapse after seemingly eﬀective anticancer treat-
ments.
Nevertheless, studies performed in vivo are often long and complicated to reveal detailed
mechanistic insights of tumor relapse. This is why three-dimensional cell cultures have pro-
gressively taken more importance, as they reduce the complexity of in vivo experiments
while allowing organotypic growth and studies at single cell level, with respect to cellular
organization and position within a tumor (Jechlinger et al., 2009).
Trying to shed light onto the mechanisms of targeted therapy resistance is of extreme im-
portance. Characterization of the molecular mechanisms responsible for tumor relapse has
become a major focus in the cancer ﬁeld, and the relevance of CIN in patient outcome sug-
gests that the CIN status could be exploited in the clinical setting. For these reasons, the
present work aimed at the study of CIN in the breast tissue using a mouse model that would
faithfully mimic human disease.
Cancer is still a devastating disease and continuous eﬀort should be implemented to study
and understand its molecular biology.
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Aims
Several questions are still open regarding the connections between oncogene driven breast
cancer and chromosome instability.
Analysis of human samples has linked CIN either to tumor onset or progression, and there is
a strong correlation between aneuploidy, poor patient prognosis and relapse. Among diﬀerent
mechanisms generating CIN in tumors, over-activation of the mitotic checkpoint has been
frequently observed. In particular, gene expression proﬁling of human breast carcinomas has
highlighted that Mad2, an essential component of the SAC, is commonly up-regulated.
Despite the strong evidence supporting the role of CIN in human breast tumors, so far,
no mouse model able to reconcile this aspect with the acknowledged concept of oncogene
dependence has been generated. As consequence, the role of CIN in oncogene driven breast
tumorigenesis has not been deeply investigated.
For these reasons, we generated new mouse models of breast cancer, crossing mice over-
expressing the Mad2 protein together with oncogenes (Her2 or MYC) known to be prominent
in human patients. This way, we were able to:
 Faithfully model human disease by introducing CIN into established mouse models of
breast cancer,
 Study the role of CIN in breast tumor initiation, progression and relapse,
 Understand the molecular mechanisms of cancer relapse in the face of CIN.
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Chapter 2
Materials and Methods
2.1 Genetically modiﬁed mouse models
2.1.1 Transgenic mice
All the transgenic mouse lines used in these studies were previously generated: TetO-Her2
(Moody et al., 2002), TetO-MYC (D'Cruz et al., 2001), TetO-Mad2 (Sotillo et al., 2007),
MMTV-rtTA (Gunther et al., 2002). All mice were on a mixed 129/Bl6/FVB background.
2.1.1.1 Animal housing and husbandry
All mouse procedures were approved by the European Molecular Biology Laboratory Mon-
terotondo Ethical Committee (Monterotondo, Italy) and were in accordance with national
and European regulations.
Animals were group housed and kept on a 12h light, 12h dark cycle (lights on at 7 a.m.)
with constant ambient temperature (21.5±1°C) and humidity (55±8%). Mice were weaned
at 3 weeks of age and housed in same sex groups in 3-5 per cage with pellet food and water
ad libitum. Immuno-compromised mice were housed in pathogen-free areas and monitored
for welfare and health.
2.1.1.2 Doxycycline diet
At 9 weeks of age virgin females were switched to a doxycycline-enriched diet. Doxycyline
(625 mg/kg) was administered in impregnated food pellets (Harlan). Upon diet switch, mice
did not show diﬀerences in food intake.
2.1.1.3 Animal monitoring
Animals set on a doxycycline diet were weekly monitored for the emergence of primary tu-
mors, as well as overall condition, including appearance, posture, behavior and physiological
responses, food and water intake. A caliber (VMR) was used to measure tumor size.
Experiments were completed before tumor development or tumor associated disease caused
death or a signiﬁcant deterioration in the host.
Humane endpoint stage was determined according to tumor size (20 mm diameter - if the
animal had more than one tumor, this size was the maximum allowable size for all tumors
combined) and the presence of one or more criteria for euthanasia (interference with a vi-
tal physiological function, labored breathing, prolonged dehydratation, muscle atrophy and
signs of lethargy and lack of physical activity, tumor ulceration or necrosis for more than
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72h). At humane endpoint stage mice were euthanized to collect primary tumor samples.
Otherwise, if needed for relapse monitoring studies, they were set back to a normal diet or
biopsied (see 2.1.2.3). Tumors were allowed to regress and mice were constantly monitored
for tumor recurrence.
2.1.1.4 Animal genotyping
Genotyping was performed by PCR using genomic DNA from tail tissue after 16h digestion
(50 mM KCl, 10 mM Tris pH 8.0, 2 mM MgCl2, 0.45% (v/v) NP-40, 0.45% (v/v) Tween 20,
1 mg/ml proteinase K) at 56°C. Proteinase K (Roche) was inactivated following incubation
at 85°C for 30 minutes. PCR ampliﬁcation was used for transgenes detection in somatic
DNA. One µl of each sample supernatant was used for PCR reaction. PCR mastermix
was as follows: 0.25 pmol/µl FW primer, 0.25 pmol/µl RW primer, 200 µM dNTPs, Taq
Polimerase 1 U/20µl, Dream Taq Green Buﬀer (Thermo Scientiﬁc) 1X. See Table 2.1 for
complete primers list. PCR conditions were as follows: 95°C for 1', 2x [95°C for 15, 64°C
for 15, 72°C for 1'30], 2x [95°C for 15, 61°C for 15, 72°C for 1'30], 20x [95°C for 15,
58°C for 15, 72°C for 1'30], 10x [9°C for 15, 55°C for 15, 72°C for 1'30], 72°C for 10'.
PCR products were run on a 1.5% agarose (Sigma) gel with ethidium bromide (Sigma) and
visualized with Molecular Imager® GelDocTM XR+ instrument (Biorad).
Mouse line FW RW
TetO-HA-
Mad2
CCATCCACGCTGTTTTGACCTC GGCTTTCTGGGACTTTTCTCTACG
TetO-Her2 GACTCTCTCTCCTGCGAAGAATGG CCTCACATTGCCAAAAGACGG
TetO-MYC TAGTGAACCGTCAGATCGCCTG TTTGATGAAGGTCTCGTCGTCC
MMTV-
rtTA
GTGAAGTGGGTCCGCGTACAG GTACTCGTCAATTCCAAGGGCATCG
Table 2.1: Forward and reverse sequence of primers used for mouse genotyping.
2.1.2 Surgical techniques
Mice were subjected to surgery only if overall condition was judged adequate prior to pro-
cedure. All surgeries were performed on isoﬂuorane (Esteve) anesthetized mice. Surgical
bench was cleaned and sterilized according to guidelines. Autoclaved, disinfected surgery
tools were used. Mice were placed onto a heating pad to prevent decrease of body tem-
perature. Depilatory cream (Veet) was used to shave the area of interest and, afterwards,
exposed skin was disinfected. After surgery, skin wounds were closed using suturing aids
(Peters surgical) and 3M Vetbondt tissue adhesive (3M Animal Care Products). Subsequent
to surgery, mice were housed into a clean cage placed onto a heating pad. After surgical
intervention animals were fed with the corresponding diet complemented with DietGel Re-
covery (Clear H2O) nutrient. Prior to any further experiment, mice were let to recover at
least for one week.
2.1.2.1 Removal of abdominal mammary glands
Virgin, doxycycline naïve females were subjected to surgery at an age of 8 to 9 weeks. A
small incision (1 cm length) was practiced in the abdominal area of the skin. Mammary
glands were gently detached from muscles and skin, then resected and placed onto a sterile
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dish. Disinfection prior to suture was carefully carried out both in internal and external
abdominal area.
2.1.2.2 Mammary fat pad injection of abdominal mammary glands
21 days old immune-compromised Rag 1-/- mice (Charles River) were used for mammary fat
pad injection. Unlargae mammary glands were removed as described in Brill at al. (Brill
et al., 2008), and further processed (see Histological and immunohistochemical analysis).
Dissociated primary tumor cells were resuspended in 1:1 cells:matrigel (Trevigen Inc.). 10
µl of 1:1 mixture were injected into each cleared fat pad using a 250 µl syringe (Hamilton).
injection
stroma
fat pad
epithelial ducts
21 days months
A B
line of surgery for 
cleaning
lymphnode
Figure 2.1: Mammary fat pad clearance and injection of immune-compromised Rag 1-/- mice.
A) Schematic representation mammary gland removal of 21 days old females. The originating center of the
mammary gland tree is called unlargae and is resected in order prevent its branching into the fat pad. 1:1
mixture cells:matrigel (Trevigen Inc.) was injected into the fat pad, allowing new cells to colonize and grow
into a physiological environment. B) Carnoy staining (see 3.2.1) of cleared mammary gland. The mammary
gland unlargae is close to the lymph node, which marks the site of resection for surgery. (Panel A taken
from (Brill et al., 2008))
2.1.2.3 Primary tumor biopsy
According to ethical guidelines, a maximum of 2 tumor biopsies (3 mm biopsy punch, Miltex)
per mouse was carried out. After disinfection of surgical area, the mouse was shaved (Veet)
only along the site of incision. Nude skin was disinfected, then cut and gently detached
from underneath tissue. Biopsies were taken with biopsy punch and immediately placed into
10% neutral buﬀered formalin solution (Sigma). Surgical area was throughout disinfected
with sterile gauze immersed into clorexyderm solution. Wound was sutured with suturing
aids (Peters surgical) and 3M Vetbondt tissue adhesive (3M Animal Care Products). After
surgery, mice were given carprofen enriched-diet for pain management (Clear H2O) and
housed in separate cages. Mice were daily checked to ensure health status until the wound
was completely healed.
2.1.2.4 Necropsy
Mice were euthanized through cervical dislocation or CO2 suﬀocation. Inferior vena cava
was cut and mice perfused with PBS 1X from the left ventricle of the heart. Tracheal PBS
1X perfusion was performed to eliminate residual blood from the lungs. Samples were ﬁxed
in a 10% neutral buﬀered formalin solution (Sigma) over night for histological analysis or
snap frozen in liquid nitrogen.
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2.2 Histological and immunohistochemical analysis
2.2.1 Whole mount of mammary glands
Mammary glands were spread onto superfrost slides (Thermo Scientiﬁc), allowed to dry and
placed for 1 hour in Carnoy's ﬁxative (methanol:acetic acid, 3:1). Tissues were stained O/N
with Carmine Alum stain (Bio Optica), then de-stained with acidic alcohol for the desired
amount of time. Fat pad was cleared in xylenes and slides were mounted with DPX mountant
(VWR).
2.2.2 Hematoxylin and Eosin staining (H&E)
Paraﬃn embedded samples were sectioned at 5 µm with RM 2135 microtome (Leica) and
placed onto superfrost slides (Thermo Scientiﬁc). Hematoxylin QS (Vector) and Eosin 1%
(Bio optic) staining was performed according to standard protocols. Slides were analyzed at
LMD 7000 microscope (Leica).
For the quantiﬁcation of lung metastasis, 5 µm sections were taken every 150 µm and stained
with H&E.
2.2.3 Immunohistochemistry analysis
5 µm sections were de-paraﬃnizsed, re-hydrated and antigen retrieval was performed in
0,09% (v/v) unmasking solution (Vector) for 30 minutes in a steamer. Endogenous hydro-
gen peroxidase activity was inactivated with 10% H2O2 solution (Sigma). After, sections
were blocked with blocking buﬀer (10% serum in PBS 1X), incubated with primary anti-
body and then, washed twice, 5 minutes each, with PBS 1X. Incubation for 30 minutes with
biotinilated antibody followed (Vectastain® ABC kit, Vector Laboratories). After antibody
washing, sections were incubated with HRP conjugated antibody and revealed with DAB
Peroxidase Substrate kit (Vector). Slides were contra-stained with hematoxylin QS (Vector),
de-hydrated and mounted with DPX mountant (VWR). Slides were analyzed at LMD 7000
microscope (Leica).
Primary antibodies: HA (Roche, 11867423001) 1:200 dilution, MYC (Cell Signaling, 56055)
1:1000.
2.2.4 Immunoﬂurescence of FFPE samples
5 µm sections were cut from FFPE (formalin ﬁxed paraﬃn embedded) samples onto super-
frost slides (Thermo Scientiﬁc). Slides were de-paraﬃnized washing them twice in xylenes
(Sigma) for 15 minutes and re-hydrated in EtOH. Then, antigen retrieval was perfomed and
slides were permeabilized in 0.5% Triton X-100 diluted in PBS 1X for 45 minutes. Slides
were washed three times in PBS 1X, each time 5 minutes. Blocking with 5% goat serum
(Jackson ImmunoResearch) in PBS 1X for 1 hour followed. Primary antibodies were in-
cubated at room temperature for 1 hour and a half. Slides were washed three times for 5
minutes in PBS 1X, then incubated with AlexaFluor® conjugated secondary antibodies (Life
Technologies; dilution 1:1000) directed against the host species of the primary antibody for
1 hour at room temperature in the dark. Slides were again washed in PBS 1X, then stained
with DAPI (Life Technologies; concentration 1 µg/ml) and mounted with 20% (w/v) Mowiol
mounting medium. Slides were analysed at LMD 7000 microscope (Leica).
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Mowiol mounting medium was prepared by the Histology Facility as follows: 5 g of Mowiol
were dissolved in 25 ml of mQ water at 55 °C, overnight with constant shaking. After, it
was aliquoted and stored at +4 °C.
Primary antibodies: Citokeratin 8, Endo-A (DSHB, TROMA-I) 1:200 dilution, Keratin 14
(Covance, PRB-155P) 1:1000 dilution.
2.3 Biochemical procedures
2.3.1 RNA extraction and qPCR analysis
2.3.1.1 RNA extraction
Snap frozen tissue was homogenized in a mortor. Frozen powdered tissue was collected
with 800 µl ml of ice cold TRIzol® reagent (Ambion) and put into a 1.5ml eppendorf tube.
Samples were incubated at RT for 10 minutes. Next, 200 µl of chloroform was added.
Samples were vigorously shaken for 15 seconds and incubated at RT for 3 minutes. Samples
were centrifuged at 15000 rpm, 15 minutes at 4°C. Aqueous phase was separated in a new
tube and processed for RNA precipitation and puriﬁcation. 500 µl of isopropanol (Sigma)
and 1 µl of linear poliacrylammide (Sigma) were added. Samples were incubated at RT
for 10 minutes, then centrifuged at 12000 rpm, 10 minutes, 4°C. Supernatant was removed
and the pellet washed with 1 ml of 75% EtOH. Next, samples were centrifuged at 7500
rpm, 5 minutes, 4°C. Supernatant was discarded and pellet allowed to dry at RT. RNA was
resuspended in 30 µl of RNAse free water.
2.3.1.2 Genomic DNA digestion
Contaminations of DNA were eliminated using TURBODNA-freeTM kit (Ambion). TURBOTM
DNAse (2 Units/µl) was inactivated and RNA was further puriﬁed using RNeasy Mini kit
(Qiagen).
2.3.1.3 Determination of RNA yield
RNA concentration was measured using Qubit® RNA Assay Kit (Invitrogen, Q32855). 500
ng of RNA were loaded on a 1% agarose gel to determine RNA integrity.
2.3.1.4 cDNA synthesis
200 ng of puriﬁed RNA were used for cDNA synthesis. The reaction was carried out with
Super Script® III RT kit (Invitrogen) or Quantitect Reverse Transcription Kit (Qiagen).
2.3.1.5 qPCR
Quantitative PCR was performed using SYBR Green qPCR mastermix (Applied Biosystems)
according to manufacturer's instructions in Lightcycler® 480 System instrument (Roche).
PCR reaction program was as follows:
See Table 2.3 for complete list of primers. The fold changes in gene expression were
calculated using the ∆∆Ct method.
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Step
Temperature
(°C)
Time (s) Cycles
Denaturation 95 300 1X
Denaturation 95 10
45XAnnealing 60 15
Elongation 72 10
Denaturation 95 5 1X
Annealing 65 60 1X
Denaturation 95 N/A Continuous
Cooling 40 10 1X
Table 2.2: Detailed qPCR program.
FW RW
Snail 1 TCCAAACCCACTCGGATGTGAAGA TTGGTGCTTGTGGAGCAAGGACAT
Rat Her2 TGTACCTTGGGACCAGCTCT GGAGCAGGGCCTGATGTGGGTT
HA-Mad2 TCCCAGAAAGCCATACAGGA GTCCCGATTCTTCCCACTTT
L37 TCTGTGGCAAGACCAAGATG GACAGCAGGGCTTCTACTGG
Actin B GCTTCTTTGCAGCTCCTTCGT ACCAGCCGCAGCGATATCG
Table 2.3: Forward and reverse qPCR primer sequences.
2.3.2 Sequencing
2.3.2.1 Sample preparation
50 ng of cDNA were used to amplify fragments of interest. Primers and relative annealing
temperatures are indicated in Table 2.3.
PCR products were puriﬁed using QIAquick PCR puriﬁcation kit (Qiagen). 5 µl of PCR
product were used to synthetize forward and reverse strand for sequencing (Big dye termi-
nator, Invitrogen). Products were precipitated at 13200 rpm, 20 minutes, RT in 64 µl EtOH
100% and 16 µl mQ water. The supernatant was removed and the pellet was washed with 400
µl of EtOH 70%. After discarding the supernatant, pellet was air dried, then resuspended
in 10 µl of mQ water. 4 µl of DNA suspension was added to 16 µl of deionised formammide
and given for sequence to the in-house facility.
FW RW
Ampliﬁcation
parameters
rtTA
TGATTAACAGCGCATTAGAG
CTGC
AAAGTGGGTCCGCGTACAG 60°C, 40 cycles
Kras GTAAGGCCTGCTGAAAATG GTGAATATCTTCAAATGAT 57°C, 40 cycles
Hras
AGAATACAAGCTTGTGGTG
GTGG
CCTGTACTGATGGATGTC
CTCG
57°C, 40 cycles
Nras
GGTCTCCAACAGCTCAGGTT
GAAG
GTACCTGTAGAGGTTAATATC
TGCA
57°C, 40 cycles
Table 2.4: Forward and reverse primers for sequencing with relative PCR conditions.
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2.3.2.2 Sequence analysis
Sequences were analysed with 4Peaks software. Mutations were validated only when present
both in forward and reverse strand.
2.3.3 Comet assay
2.3.3.1 Slide preparation
Superfrost Plus slides (Thermoscientiﬁc) were dipped in 1% liquid agarose (Sigma). The
excess of agarose was removed and slides were dried at 37°C.
2.3.3.2 Primary tumor cells preparation
In order to detect DNA damage at single cell level, primary tumor cells - prepared as de-
scribed in 2.4.2 - were cultured in 6 well collagen-coated plates (BD Biosciences) for 24h in
MEBM media (Lonza). Media was changed and, after 24h, cells were collected by trypsiniza-
tion (0.25% trypsin, Gibco). Trypsinisation was inactivated using DMEM (Lonza) 25 mM
Hepes (Gibco), 10% Tet Free FBS (Clontech), 1% Pen/Strep (Gibco). Cells were incubated
in DNase I (5 mg/ml. Roche) for 5 minutes. After centrifugation at 1000 rpm, 5 minutes,
RT cells were resuspended in 1 ml of PBS 1X supplemented with heparin (4 µg/ml, Sigma).
Cells were centrifuged again at the same settings and the supernatant was removed. Pel-
let was resuspended in 140 µl of 1% liquid low melting point agarose. Two drops of equal
volume were seeded onto previously agarose coated slides, then, quickly covered with 22x22
coverslips and incubated at 4°C for 5 minutes.
2.3.3.3 Lysis
1 ml of Triton X-100 was freshly added to 100 ml of lysis solution (2.5 M NaCl, 0.1 M EDTA,
10 mM Tris, pH 10). Coverslips were removed from slides and placed in this solution on a
horizontal staining jar for 1 hour at 4°C.
2.3.3.4 Alkaline treatment
Slides were incubated for 40 minutes in electrophoresis solution (0.3 M NaOH, 1 mM EDTA).
Solution was poured into electrophoresis tanks at 4°C one hour before use. Slides were placed
onto the platform tank, immersed in solution, forming complete rows. Any gap was ﬁlled
with blank slides.
2.3.3.5 Electrophoresis and neutralization
Electrophoresis was done at 25V for 30 minutes. After, slides were washed 3 times for 5
minutes in neutralizing buﬀer (0.4 M Tris HCl, pH 7.5).
2.3.3.6 Staining and storage
Slides were stained with Hoechst 1 mg/ml and analysed at LMD 7000 microscope (Leica).
Slides were stored at 4°C in a moist chamber.
2.3.3.7 Comets analysis
Comets were analyzed using the OpenComet software. Results were plotted as percentage
of DNA contained in the comet tail.
33
2.4 Cell culture
2.4.1 Primary mammary epithelial cell culture
Mammary glands from 9 weeks old, doxycycline naïve transgenic mice were digested and
cultured as in Jechlinger et al., 2009 and Lee et al., 2007.
2.4.2 Immunoﬂurescence of 3D cell cultures
3D gels were digested for 30 minutes at 37°C with 2.5 µl/ml LiberaseTM research grade
(Roche) and 2.5 µl/ml Collagenase type 3 (Worthington), washed with PBS 1X, and ﬁxed
for 10 minutes in 4% parafolmaldehide. Washes for 15 minutes in IF buﬀer 1X followed
for three times. Blocking in IF 1X buﬀer plus 10% goat serum (Jackson Immunoresearch)
followed for 1 hour. Then, gels were further blocked in IF buﬀer 1X plus 10% goat and 10
µg/ml goat anti-mouse F(ab)2 fragments (Jackson Immunoresearch) for 30 minutes. Pri-
mary antibodies were incubated O/N at 4°C. Primary antibodies were washed three times
for 20 minutes in IF buﬀer 1X; Alexa conjugated secondary antibodies (Invitrogen, 1:1000
dilution) were incubated for 1 hour at room temperature. Three IF 1X washes followed, then
gels were further washed with PBS 1X. DAPI (Roche) was used at 0.5 ng/ml in the last IF
1X wash. Gels were mounted with the anti-fade agent Vectashield (Vector laboratories).
1X IF buﬀer: 130 mM NaCl (Sigma), 7 mM Na2HPO4 (Sigma), 3.5 mM NaH2PO4 (Sigma),
7.7 mM NaN3 (Merck), 0.1 % BSA (Sigma), 0.2 % Triton X-100 (Sigma), 0.05 % Tween
(Sigma), pH 7.4.
Primary antibodies: Lamin B1 (Abcam, ab16048) 1:1000 dilution, E-cadherin (Invitrogen,
13-1900) 1:400 dilution, ZO-1 (Invitrogen, 61-7300) 1:500 dilution, HA (Covance, A594-101L)
1:2000 dilution.
2.4.3 Ex vivo breast primary tumor culture
2.4.3.1 Primary tumor digestion
Primary tumors were collected from euthanized animals. Tissue was mechanically dissoci-
ated, incubated for 3 minutes with Red Blood Cells Lysing Buﬀer Hybri-Max (Sigma) and
centrifuged at 1000 rpm, 5 minutes, RT. Pellet was incubated in 5 ml DMEM media (Lonza)
25mM Hepes (Gibco), 1% Pen/Strep (Gibco), 2.5 µl/ml LiberaseTM research grade (Roche)
and 2.5 µl/ml Collagenase type 3 (Worthington) for 1h. After PBS 1X wash, tumors were
incubated in 0.25% trypsin (Invitrogen) for 30 minutes. Trypsinizsation was inactivated
using DMEM (Lonza) 25 mM Hepes (Gibco), 10% Tet Free FBS (Clontech), 1% Pen/Strep
(Gibco). Cells were incubated in DNase I (5 mg/ml, Roche) for 5 minutes. Dissociated cells
were resuspended in serum-free MEBM media (Lonza) with supplements (Lonza, CC-3150),
ﬁltered with 70 µm and 40 µm cell strainers, then counted (LabTek II chamber, Thermo
Scientiﬁc) in preparation for injection into cleared fat pad.
2.4.3.2 Primary tumor 3D culture
Dissociated primary tumor cells were cultured in 3D matrigel (Trevigen Inc.). 10,000 cells
were seeded in 100 µl cell:matrigel droplets. Cells were fed with MEBM media (Lonza).
Media was changed every 48h. Cells were monitored for growth every 2/3 days.
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2.4.4 Metaphase spreads
2.4.4.1 Cell preparation
Primary tumor cells were cultured in 6 well collagen-coated plates (BD Biosciences) for 24h
in MEBM media (Lonza). Aphidicolin (3 µg/µl Sigma) block for 8-10h followed. After
washout, cells were incubated O/N with colcemid (0.015 µg/µl). The next day, colcemid was
added up to 0.05 µg/µl and cells were incubated for 2h.
2.4.4.2 Chromosome spreads harvesting
After mitotic shake-oﬀ, media was collected into a 14 ml corning tube. Cells were washed
with PBS 1X and removed from the plate with 0.25% trypsin (Invitrogen) treatment. Try-
psinization was inactivated using DMEM (Lonza) 25mM Hepes (Gibco), 10% Tet Free FBS
(Clontech), 1% Pen/Strep (Gibco) and cells were collected into the same tube. Cells were
centrifuged at 1000 rpm, 5 minutes, RT. Supernatant was removed and cells were resuspended
in 1.5 ml of supplemented MEBM media (Lonza). Hypotonic solution (75mM KCl) was
added very slowly, drop by drop, along the wall of the tube up to 10 ml. Cells were incubated
at 37°C for 20 minutes. After, 3-4 drops of ﬁxative solution (methanol:acetic acid 3:1)
were added and tubes gently inverted. Cells were centrifuged at 1000 rpm, 5 minutes, RT.
Supernatant was removed, leaving 1 ml behind in which to resuspend the pellet by ﬂicking
the tube. Fixative solution was added up to 10 ml; meanwhile, the tube was ﬂicked from
time to time to throughout allow cell ﬁxation. Cells were centrifuged 1000 rpm, 5 minutes,
RT.
The last step was repeated 2-3 times for a total of 3-4 ﬁxations. After this step, cells were
kept on ice.
2.4.4.3 Chromosome spreads preparation
Superfrost slides (Thermo scientiﬁc) were immersed in ﬁxative solution and stored at -20°C
O/N. Paper tissues were wet with water and put onto a heating block set at 80°C to produce
hot vapors. After ﬁxation, cells were resuspended in 100-500 µl of fresh ﬁxative solution by
ﬂicking/vortexing the tube. Cells were splashed onto superfrost slides on top of the heating
block. Fixative was let partially evaporate, then, new ﬁxative solution was added on the
slide. After, slides were dried on the heating block for 5-10 minutes and O/N at RT.
Slides used for M-FISH analysis were stored at RT for 10 days maximum; afterwards, they
were kept in boxes with hygroscopic salts at -20°C.
2.4.4.4 M-FISH analysis
M-FISH analysis was performed using the 24XCyte kit from Metasystem (Zeiss) according
to manufacturer's instructions. This technique was performed at the Chromosome Dynamics
Core, The Welcome Trust Center for Human Genetics, Oxford, UK.
2.5 Statistical analysis
Data are presented as mean ± SEM. Statistical signiﬁcance was determined using GraphPad
Prism® software. P-values < 0.05 were considered statistically signiﬁcant.
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Chapter 3
Results
3.1 Generation of CIN mouse models of breast cancer
CIN plays a pivotal role in the progression and recurrence of malignancies in patients. How-
ever, as mentioned in the introduction, no mouse model that would combine chromosome
instability in oncogene-driven breast tumorigenesis has, so far, been generated. In fact,
mouse models with activating oncogenes often result in karyotipically stable tumors, a si-
tuation that does not entirely recapitulate the human disease (Duijf et al., 2012).
We crossed tetracycline inducible Mad2 mice (Sotillo et al., 2007) with mice that express
either Her2 (Moody et al., 2002) or MYC (D'Cruz et al., 2001) in a MMTV (Mouse Mam-
mary Tumor Virus (Gunther et al., 2002)) background, generating the TetO-Her2/TetO-
Mad2/MMTV-rtTA and TetO-MYC/TetO-Mad2/MMTV-rtTA models. Herein, as point of
nomenclature, these mice will be referred to as TI-Her2/Mad2 and TI-MYC/Mad2 - where
TI stands for tetracycline inducible - or triple transgenic mice. In the same way, mice bearing
only one of the transgenes will be mentioned as TI-Her2, TI-MYC and TI-Mad2 or double
transgenic.
In these models the expression of both transgenes can be regulated speciﬁcally in the mam-
mary gland - under the control of the MMTV promoter - by administration or withdrawal of
doxycycline. Doxycycline, bound to the rtTA transcription factor, allows transgene expres-
sion; contrariwise, absence of this compound prevents exogenous gene transcription, thereby
shutting oﬀ the production of transgenic proteins (Figure 3.1). The latter is a key point in
this study, in particular considering oncogenes as the driving force of tumor formation. In
fact, targeting oncogene dependence is the rationale behind current targeted therapies and
this system, in mice, oﬀers the possibility of perfectly mimicking the actual therapeutical
protocol administered to patients. In this respect, it is of worth pointing out that only drugs
speciﬁc for the Her2 receptor have been developed, while c-MYC is still an un-druggable
oncogene.
Therefore, the TI-Her2/Mad2 and TI-MYC/Mad2 models, in comparison to TI-Her2, TI-
MYC and TI-Mad2, gives us the possibility to:
 Faithfully recapitulate human disease
 Study the process of primary tumor formation in the presence of doxycycline
 Mimic targeted therapy, upon doxycycline withdrawal
 Investigate the inﬂuence of Mad2 overexpression in the primary lesion and in the relapse
process
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Mouse line Description Reference
TetO-HA-
Mad2
Mice bearing the Mad2 cDNA fused with an HA tag.
TetO repeats are cloned upstream the transgene
(Sotillo et al., 2007)
TetO-Her2
Mouse line expressing an activated form of the Her2
oncogene under doxycycline control
(Moody et al., 2002)
TetO-MYC
Mouse line over-expressing exon 2 and 3 of c-MYC
human oncogene
(D'Cruz et al., 2001)
MMTV-
rtTA
Mouse line where the rtTA is under the control of the
Mouse Mammary Tumor Virus promoter
(Gunther et al.,
2002)
Table 3.1: Description of mouse lines. Each mouse line used in these experiments is brieﬂy described
and original papers cited as reference.
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Figure 3.1: The Tet-On tetracycline inducible system. The tetracycline inducible system is made of
two components: the rtTA transcription factor - under the control of the tissue speciﬁc MMTV promoter -
and the TetO repeats cloned upstream the transgene of interest. Only in the presence of doxycycline (right
panel) the rtTA dimer is able to bind to the TetO repeats and drive transgene expression. In our case, Her2
or c-MYC are the oncogenes used to drive tumor formation.
3.2 Mad2 over-expression is detrimental to primary tu-
mor formation
3.2.1 Mad2 over-expression delays mammary gland tumorigenesis
in vivo
In order to compare primary breast tumor latency, cohorts of experimental and control mice
were raised. TI-Mad2, TI-Her2 and TI-Her2/Mad2, TI-MYC and TI-Mad2/MYC mice were
generated and considered as experimental cohorts. Transgenic virgin females were switched
to a doxycycline-enriched diet after complete development of the mammary gland (9 weeks
of age), thus allowing transgene expression. Mice were weekly monitored to determine the
appearance of malignant nodules.
Along with those mice, several control cohorts were raised. Transgenic mice bearing the
same genotype as above mentioned animals, were fed doxycycline free food to exclude trans-
38
gene leakiness. To rule out any doxycycline eﬀect and uncontrolled transgene activation by
an endogenous mechanism, mice bearing only the rtTA module or the TetO repeats fused
with a transgene were aged and fed with doxycycline impregnated food. None of these mice
(n=51) developed mammary gland tumors in the timeframe considered for experimental
purposes (500 days). Thus, this result conﬁrms that the tetracycline inducible system used
is these mice is tightly controlled and activated only in the presence of doxycycline.
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Induced TI-Mad2Never induced control
Figure 3.2: Mammary glands from control and induced TI-Mad2 mice do not develop primary
tumors. a,b) Panels showing H&E staining of mammary glands from aged control mice. Normal mammary
glands are characterized by the presence of ducts and terminal end buds, surrounded by adipose tissue. c,d)
Immunoﬂuorescence (IF) against K8 (green) and K14 (red) in normal mammary glands, showing distinct
luminal and basal polarization and the characteristic organization of double layered epithelium. e) H&E
staining of doxycycline TI-Mad2 animal. At aged-matched samples (500 days), TI-Mad2 mammary glands
show the same structural organization than controls. f) HA IHC of TI-Mad2 induced mammary gland
showing HA-Mad2 transgene expression. H&E and HA IHC scale bar 50 µm; IF scale bar 27.8 µm.
TI-Mad2 (n=20) mice do not develop mammary gland tumors upon doxycycline induction
in the timeframe of analysis (500 days), suggesting that Mad2 over-expression by itself is
not suﬃcient to drive breast cancer initiation, at least under the control of the MMTV
promoter. In fact, it was surprising to observe that, Mad2 over-expression in vivo induces a
delay in primary tumorigenesis, irrespective of the oncogenic background (Figure 3.3). TI-
Her2/Mad2 and TI-MYC/Mad2 mice develop primary tumors with statistically signiﬁcant
longer latency compared to TI-Her2, TI-MYC animals. These results are in contrast with
what has been previously published in a CIN model of lung tumorigenesis (Sotillo et al.,
2010) highlighting that, in mammary epithelial cells, Mad2 over-expression is detrimental
for tumor initiation.
3.2.2 Mad2 over-expression aﬀects tumor multiplicity in vivo in
Her2 driven breast tumorigenesis
Given the previous ﬁndings, we sought to understand if Mad2 over-expression, in combina-
tion with an oncogene, could not only, delay primary tumorigenesis but also aﬀect tumor
multiplicity in vivo. Female mice have ten mammary glands and, potentially, all of them
could develop tumors with the same probability. However, this was rarely observed in our
cohorts (only one case in a total number of 190 experimental mice), with the average number
of tumors per animal being lower. Therefore, we counted the number of primary tumors per
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Figure 3.3: Mad2 over-expression delays breast cancer formation, irrespective of the oncogenic
background. Kaplan Meyer plot of primary tumor latency in TI-Mad2 (grey), TI-Her2 or TI-MYC (green)
and TI-Her2/Mad2 or TI-MYC/Mad2 (blue) lines. Panel A and B respectively. Timepoint 0 indicates when
mice were set on a doxycycline diet (9 weeks of age). Each stair on the lines represents a positive event, that
is, a mouse that developed a primary tumor, plotted against time (days). TI-Mad2 mice did not develop
primary tumors in this timeframe. Mice over-expressing Mad2 in combination with an oncogene, have a
delayed tumorigenesis compared to mice bearing the oncogene alone (TI-Her2 median latency 94 days, n=61
and TI-Her2/Mad2 median latency 138 days, n=68; TI-MYC 224 days, n=46 and TI-MYC/Mad2 321 days,
n=36. Mantel-cox test, p-value < 0.001)
animal arising among double transgenic mice and compared it with the triple transgenic
counterpart. Mad2 over-expression did aﬀect tumor multiplicity when in combination with
the Her2 oncogene. TI-Her2 mice developed an average of 5.2 tumors per mice, (n=53),
while TI-Her2/Mad2 mice had, a signiﬁcantly lower number of tumors (3.984) per animal
(n=62; t-test, p-value=0.0022). In the case of MYC, mice develop in average 1.7 primary tu-
mors (n=45) and in the combination of MYC with Mad2 the number is similar (1.5; n=30).
The comparison between these two cohorts did not results in statistical signiﬁcance (t-test,
p-value>0.05).
All together, this result and the fact that Mad2 strongly delays breast cancer, highlights
the tumor suppressive role of Mad2 in mammary gland tumorigenesis, even if evident only
in the Her2 oncogene background. Why the same eﬀect was not observed in case of MYC
is not fully understood. However, one could hypothesize that in the case of MYC driven
tumorigenesis, the average number of tumors per animal (1.7) is, per se, low. Thereof, even
if Mad2 over-expression could have an eﬀect in suppressing tumor multiplicity, this would
be very diﬃcult to detect in vivo. However, we could also hypothesize that Mad2 eﬀect is
dependent on the oncogenic background. Both Her2 and MYC are known to induce cell pro-
liferation when over-expressed. The combination with Mad2 is predicted to over-activate the
checkpoint and prolong mitosis, which potentially induces cell death (see 1.2.2 and 3.2.3). If
this process is constantly ongoing because of sustained transgenes over-expression, the tissue
must ﬁnd a balance between cell death and regeneration. In the Her2 background, constant
cell loss may gradually lead to an exhausted tissue and, as consequence, decreased tumor
multiplicity. When MYC is deregulated, instead, cells are already sentisized to apoptosis
(Hoﬀmann and Liebermann, 2008). Therefore, the combination with Mad2 may not result
in an additive eﬀect, but simply leave invariated the MYC induced outcome.
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Figure 3.4: Tumor multiplicity is aﬀected by Mad2 over-expression. A, C) Number of tumors
arising in each experimental animal, TI-Her2 (n=53) and TI-MYC (n=45) (green), TI-Her2/Mad2 (n=62)
and TI-MYC/Mad2 (n=30) (blue). Tumor multiplicity was aﬀected only in the Her2 background. B,D)
Distribution of mice in diﬀerent classes depending on the number of palpable tumors at human endpoint
stage. Diﬀerence in classes distribution was signiﬁcant only in the Her2 background (Chi-square test, p-value
< 0.0001).
3.2.3 Mad2 over-expression causes mitotic arrest in vitro
To better understand the delayed tumorigenesis induced by Mad2 over-expression we de-
cided to investigate events happening at early time points of transgene induction. In fact,
pre-tumorigenic stages are key determinants in further malignant progression and likely to
help understanding the role of Mad2 in combination with a driving oncogene. To address
this question, we resorted to a three dimensional cell culture system of primary mammary
cells (Jechlinger et al., 2009). This system has been successfully used to study the eﬀects of
two potent oncogenes in culture, MYC and Kras, and it reproduces the observed phenotypes
in vivo.
Primary mammary epithelial cells taken from virgin mice containing diﬀerent transgene
combination were grown in a matrigel based 3D culture system. Single cells develop orga-
notypic acinar spheres within 6 to 8 days of culture and, after that, transgenes were induced
by adding doxycycline to the culture media. 36h post induction, gels were ﬁxed and stained
with diﬀerent antibodies. As controls, transgenic cells with identical genotypes were grown
without the addiction of doxycycline.
Never induced control cells develop into a sphere-like hollowed structure, formed by a
single layer of epithelial cells, characterized by a strict apical-basal polarization. At this time
point, acini have reached a steady-state level where the optimal functional size is set and
cells seldom divide to maintain it. In case cell division is happening, the polar spindle is
parallel to the acinar lumen, allowing daughter cells to be integrated into the external rim
layer, upon completion of mitosis (Jechlinger et al., 2009).
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Figure 3.5: Mad2 over-expression causes mitotic arrest at early induction time point ex vivo.
a) Mammary epithelial cells grown in 3D culture develop into polarized acinar spheres. b), f) Early 36h
hours induction of Mad2 transgene induced a mild mitotic arrest without disrupting acinar organization
(Panel b, K. Rowald). c) TI-Her2 induction did not show diﬀerences compared to controls; TI-MYC induced
acini (g) developed into ﬁlled spheres. Combination of Mad2 with either oncogene (d, h) caused dramatic
mitotic arrest 36 hours after adding doxycycline. Arrows indicate mitotic arrested cells. Immunoﬂurescence:
DAPI (blue), red (HA-Mad2), Lamin B1 (green in a, b, c, d), ZO-1 (green in e, f, g, h), E-cadherin (purple).
Scale bar 7 µm.
Over-expression of Mad2 alone does not appear to disrupt the acinar organization (Figure
3.5 b). When over-expressed, we observed cells arrested at the metaphase plate, suggest-
ing that metaphase to anaphase transition was prolonged, consistent with Mad2 function
in the SAC. Overexpression of Her2 for 36h did not show any diﬀerence when compared to
uninduced cells (Figure 3.5 c). Acini were still organized and did not show an increase in
the number of mitotic cells. When cells containing the MYC transgene were induced they
started ﬁlling the acinar structure and gave rise to solid spheres. The diﬀerent phenotypes
observed between the two oncogenes, Her2 and MYC, in the 3D culture, is currently being
investigated in the lab. It is possible that cells expressing Her2 need additional factors or
stimuli from surrounding stroma cells that are lacking in vitro. Alternatively, oncogenic
MYC could be responsible of a higher proliferative input in vitro, thus generating the dif-
ference with TI-Her2 cells.
TI-Her2/Mad2 induced acini showed a signiﬁcant increase in the number of cells arrested in
mitosis (Figure 3.5 d). This phenotype was further exacerbated when Mad2 was combined
with MYC, where almost all the cells in every structure were mitotically arrested (Figure
3.5 h). A possible explanation is that the proliferation input given by the oncogenes pushes
cells into division while at the same time, Mad2 over-expression blocks most of them at the
mitotic stage. This is why we could observe this striking phenomenon only in the presence
of Mad2. The stronger the oncogene inﬂuence, the more pronounced the phenotype was -
so, in this respect, c-MYC exerts a more incisive inﬂuence at early time points.
In case of Mad2 overexpression alone or Mad2 in combination with an oncogene, mitotic
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arrested cells appeared to fall inside the lumen of the acinar structure. We hypothesized
that a prolonged mitosis could loosen cell-cell interactions, thereby promoting cell delamina-
tion (Dekanty and Milan, 2013) from the external rim. To further conﬁrm these results and
exclude the possibility of a culture artifact, data from our laboratory has shown that 4 day
induction of Mad2 in the mammary gland also leads to mitotic arrest in vivo (Konstantina
Rowald, unpublished data). Cell delamination and loss of epithelial contacts are known to
be associated with anoikis (Taddei et al., 2012). In the mammary gland tissue, the ductal
system may help the clearance of dead cells, and continuous cell elimination induced by
Mad2 over-expression might generate a selection barrier a tumor should overcome before
transformation occurs. In this context, Mad2 over-expression acts a tumor-suppressive gene
and delays mammary gland tumorigenesis (K. Rowald, manuscript in preparation).
3.2.4 Mad2 over-expression promotes tumor heterogeneity
Since we observed diﬀerences in tumor latency of mice bearing the Mad2 transgene, we
next wanted to examine if Mad2 could give rise to diﬀerent tumor types. For this purpose,
formaline ﬁxed, paraﬃn-embedded tumors taken from mice at human endpoint stage, were
analyzed for histopathological classiﬁcation by a mouse histopathologist (collaboration with
DMV Dott. Vittoria Castiglioni, Dipartimento di Patologia Animale, Igiene e Sanità Pub-
blica Veterinaria Facoltà di Medicina Veterinaria, Università degli Studi di Milano).
Primary tumors developed in TI-Her2 mice (n=18) are mostly solid multinodular carcino-
mas (60%), while the remaining ones are representative of microacinar (20%) and papillary
(20%) subtypes.
TI-Her2/Mad2 malignancies (n=33) have a broader histopathological spectrum (Figure 3.6),
with 38% being solid multinodular, 14% microacinar carcinomas, 41% tubulo papillary and
7% cribiform.
Multinodular
Cancer arising from clearly distinct nodules which together form the tumoral
mass
Microacinar Distinguished by the growth of small adjacent but distinct acinar structure
Papillary
Inﬁltrating breast cancer, characterized by well deﬁned margins and small
projections
Cribiform
Perforated growth pattern, microscopic architecture of epithelial cells growing
back to back without intervening stroma
Table 3.2: Description of solid mammary tumor subtypes.
In case of MYC driven tumorigenesis, we could not appreciate any diﬀerence in the
histopathological distribution of analyzed samples. 88% of TI-MYC primary tumors (n=16)
show a papillary phenotype, with the remaining 12% belonging to the solid carcinoma type.
When MYC is expressed in combination with Mad2, all the samples (n=24) fall uniformly
into the papillary class (Figure 3.6 C).
3.2.4.1 Mad2 over-expression is detrimental to cellular ﬁtness and selected
against
Mad2 overexpression not only delays tumorigenesis but also signiﬁcantly changes tumor mor-
phology, suggesting a role of CIN in facilitating tumor heterogeneity. To better understand
the patterns of Mad2 expression in the tumors, we took advantage of an HA tag in frame
with the Mad2 transgene. This allows us to distinguish the exogenous Mad2 present in the
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Figure 3.6: Histopathological classiﬁcation in TI-Her2, TI-Her2/Mad2, TI-MYC and TI-
MYC/Mad2 primary tumors. A) Heterogeneous histopathology (H&E staining) of TI-Her2 and TI-
Her2/Mad2 primary tumors. B, C) Distribution of analyzed primary tumors per genotype according to the
histopathological classiﬁcation in the Her2 and MYC background. Upper panels scale bar 200 µm, lower
panels 50 µm.
tumor.
Immunohistochemistry analysis of primary tumors at endpoint stage in the TI-Her2/Mad2
cohort revealed that 17.5% of the tumors do not show exogenous HA-Mad2 expression (n=10
out of 57 primary tumors analyzed). This result was further conﬁrmed at the transcript level
with RT-PCR in a smaller subset of samples. mRNA analysis and IHC of the same sample
gave concordant results, suggesting that the Mad2 transgene was not expressed and the lack
of protein was not due to post-transcriptional regulation of the mRNA (see ﬁgure 3.7).
Since Mad2 and Her2 transgenes are simultaneously regulated by the expression of rtTA
and doxycycline, we next examined the expression of Her2 in those tumors that did not
express Mad2. Interestingly, transgenic Her2 expression was induced and showed similar
levels compared to tumors were Mad2 was also upregulated. (Figure 3.7). One could argue
that levels of exogenous Mad2 induction may vary across mice. Therefore, the absence of
HA-Mad2 could simply underline a very low, non-detectable, transgene expression. However,
we could rule out this possibility comparing exogenous Mad2 expression between primary
tumors and induced mammary glands from the same animal (see ﬁgure 3.8). As previously
mentioned, tumor multiplicity in these mice is lower than the total number of mammary
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glands. Consequently, within the same animal, mammary glands that developed a tumoral
mass and mammary glands that - at the moment of euthanasia - had not developed a pal-
pable nodule were compared. This analysis brought to our attention the fact HA-Mad2
negative primary tumors had matching samples showing, instead, both transgenes expres-
sion. This result further conﬁrms the hypothesis that Mad2 over-expression is, indeed, tumor
suppressive in the formation of primary breast cancer. Speciﬁcally in these cases - even if
representing a minority of all analyzed samples - there is a strong selection against cells over-
expressing Mad2, suggesting that, in a particular context, excessive CIN is not tolerated.
Hence, in a speciﬁc tissue and environment, an optimum tolerated level of CIN should exist
(Zasadil et al., 2013). Excessive CIN could compromise genome stability in a way that is
incompatible with cell viability. These cells could be eliminated in an active process that is
speciﬁcally selecting for those clones that have lower CIN levels. Milder CIN could promote
the acquisition of genomic variability and, at the same time, preserving a certain degree of
genome stability. This would allow the adaptation to changes in tumor environment without
compromising cellular ﬁtness.
Further corroborating this ﬁnding is the analysis of primary tumor latency sub-dividing
the TI-Her2/Mad2 cohort into HA-Mad2 positive and negative tumors. HA-Mad2 negative
primary tumors developed with a longer latency than the positive ones (209.5 days, n=10
and 133 days, n=47 respectively) and the diﬀerence between the two cohorts is statistically
signiﬁcant (Mantel cox test p value=0.0025).
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Figure 3.7: Mad2 transgene expression is downregulated in a subset of TI-Her2/Mad2 primary
tumors. A) and B) Immunohistochemistry analysis performed on TI-Her2/Mad2 HA negative and positive
primary tumors. Upper and lower panels show histological features of the same sample taken at diﬀerent
magniﬁcation. Upper panels scale bar 200 µm; lower panels scale bar 50 µm. C, D) qPCR analysis of Mad2
and Her2 transgenes expression in TI-Her2 (green) and TI-Her2/Mad2 (blue) in a subset primary tumors.
The same samples were analysed for both transgenes expression (see corresponding numbers below both
graphs).
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Figure 3.8: Exogenous HA-Mad2 expression is lost in a subset of TI-Her2/Mad2 primary
tumors. A) HA IHC performed against two diﬀerent primary malignancies (a,b) and induced mammary
glands (c,d) with no palpable tumor from the same animal. Scale bar 50 µm. B) qPCR analysis for HA-
Mad2 (blue) and Her2 (green) transgenes expression in matching induced mammary gland (striped pattern)
and tumor samples (plain pattern). On the left Her2 trangene induction in TI-Her2 samples is shown. On
the right part, HA-Mad2 and rat Her2 expression in induced mammary gland and primary tumor from the
same animal are shown. TI-Her2/Mad2 primary tumor does not show exogenous Mad2 expression (dotted
square). C) Kaplan Meyer plot of primary tumor latency in triple (HA positive TI-Her2/Mad2 blue, HA
negative TI-Her2/Mad2 red) and double transgenic (TI-Her2 green) mammary gland (mg) tumor samples.
In triple transgenic animals, the graph represents the latency of all primary tumor samples analyzed by HA
IHC. In case of the TI-Her2 cohort, the latency of individual samples is plotted. The presence of a tumor
was considered as an indirect proof of Her2 transgene expression.
In case of MYC driven tumorigenesis, IHC analysis of all TI-MYC/Mad2 primary tumor
samples showed exogenous Mad2 expression (IHC analysis against the HA tag, data not
shown). Therefore, it was not possible to carry out this type of analysis in this cohort.
3.2.4.2 Mad2 over-expression causes CIN and promotes higher missegregation
rates
The previous ﬁnding prompted us to speculate that Mad2 over-expression may be the source
of genetic variability that would, ultimately, be reﬂected in the tumor phenotype.
It has already been published that Mad2 over-expression in vivo leads to the formation of
aneuploid tumors in mice (Sotillo et al., 2007, Sotillo et al., 2010). Moreover, human sample
analysis correlated higher rates of CIN and poor patient outcome (Gutierrez and Schiﬀ, 2011;
Macrinici and Romond, 2010; Smid et al., 2010). In particular, most of these studies were
carried out considering, as relevant subtype, Her2+ carcinomas. This is why we sought to
compare the karyotype of TI-Her2/Mad2 versus TI-Her2 primary tumors.
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M-FISH (T. Liehr, 2004) analysis was carried out to analyze the aneuploid status as well
as chromosomal rearrangements. Six TI-Her2 and eight TI-Her/Mad2 primary tumors were
subjected to M-FISH analysis by the Wellcome Trust Center for Human Genetics, Oxford
(total number of painted metaphases was 189 and 172 respectively). A selection of repre-
sentative M-FISH karyotypes in shown in ﬁgure 3.9.
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Figure 3.9: M-FISH analysis of control, TI-Her2 and TI-Her2/Mad2 primary tumors. A)
Transgenic mammary epithelial cells dividing in the absence of doxycycline were used as controls to de-
lineate possible technical bias. Karyotypes generally do not show any abnormalities, however occasionally
chromosome losses can be appreciated (arrow). B) and C) M-FISH karyotypes of TI-Her2 and TI-Her2/Mad2
primary tumors. Both samples show chromosome gains and losses, as well as chromosome rearrangements.
Only TI-Her2/Mad2 samples are characterized by DNA double strand breaks (arrow).
As it has already been mentioned, Mad2 is linked to aneuploidy both in vitro and in vivo.
Therefore we ﬁrst analyzed the karyotype from both genotypes (Figure 3.10 A). 69.66% of
triple transgenic cells contain an abnormal chromosome number, while only 31.43% TI-Her2
ones deviate from the diploid status (Fisher's exact test, p<0.0001). However, karyotype
analysis does not completely reﬂect the real state of aneuploidy within a tumor. In fact, a
cell characterized by loss of one chromosome and gain of another one, would still ﬁgure out as
being haploid. The number of chromosomes is still correct (in this case, 40) but this analysis
would inevitably underestimate the real rate of chromosome missegregation. Therefore, we
decided to speciﬁcally consider the fate of each chromosome in our samples to identify the
likelyhood of mitotic errors in TI-Her and TI-Her2/Mad2 primary tumors.
Single chromosome missegregation analysis pointed out both inter and intra-tumor hetero-
geneity. Aneuploidy was not limited only to one speciﬁc chromosome, suggesting that Mad2
over-expression not only induces aneuploidy but whole CIN as well. It is of note to stress the
notion that TI-Her2 samples are also characterized by whole CIN; however, this phenomenon
can be observed at signiﬁcantly higher rates in TI-Her2/Mad2 primary tumors.
As obvious causal factor, TI-Her2/Mad2 tumors tend to be more prone to missegregation
errors. In cells with close-to-diploid chromosome number, 89% of TI-Her2/Mad2 cells con-
tain, at least, one missegregation event and this is statistically signiﬁcant if compared to
double transgenic samples (79%; Figure 3.10 B). If we consider the number of missegregated
chromosomes per metaphase, both genotypes may missegregate in a broad range going from
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1 to 10 events in case of TI-Her2/Mad2 or even higher - up to 18, but only in sporadic
cases - in TI-Her2 samples. Cells that contained 1 to 5 concomitant missegregated chromo-
somes were deﬁned as bearing mild missegregation, while every cell having more than 5 was
classiﬁes as severe (Figure 3.10 C). One could hypothezise that Mad2 over-expression could
promote higher mitotic defects, therefore skewing tumor cells towards a severe missegrega-
tion phenotype. However, this analysis did not point out any diﬀerence among TI-Her2 and
TI-Her2/Mad2 primary tumors, suggesting that Mad2 over-expression is promoting higher
missegregation rates but without promoting a severe phenotype. It might be that excessive
missegregation events happening in the same cell are not compatible with cellular ﬁtness or
viability, and are, therefore, selected against in the tumorigenic process.
In fact, in both cases, there is a tendency towards the missegregation of two chromosomes
per metaphase (see table 3.3), however, this is much more prominent in the presence of
Mad2.
Number
missegre-
gated
chromo-
somes/
Metaphase
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
TI-Her2 21 11 28 12 8 3 4 4 3 2 0 0 0.6 0 0 0 0.6 0.6 0.6
TI-
Her2/Mad2
11 12 41 17 8 6 2 2 1 1 1 0 0 0 0 0 0 0 0
Control 80 10 5 2 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0
Table 3.3: Missegregation chromosome rates (%) in primary TI-Her2 and TI-Her2/Mad2
mammary gland tumors. Cells were divided into classes according to the number of missegregated
chromosomes per metaphase. For each class, values in % are given across the diﬀerent samples.
Recently, Benezra's group (Duijf et al., 2012) published a study of numerical chromo-
some aneuploiody performed on more than 43,000 human tumors. Data convincingly showed
that tumors tend to loose, rather than gain, chromosomes. In particular, the loss is skewed
towards small chromosomes but no inverse correlation was found for gains. One could think
that acquisition of genetic material may lead to a phenomenon deﬁned as proteotoxic stress,
which impairs cellular growth in a way that is proportional to the amount of extra DNA
(Torres et al., 2007). For this reason, gain would be a disfavored event compared to losses.
However, preferentially gained chromosomes are not characterized by low coding gene con-
tent, hinting at the fact that, at least in established tumors, proteotoxic stress does not
constitute a barrier for cancer survival and propagation.
On the other hand, chromosome loss has been shown to contribute to tumorigenesis via loss
of tumor suppressor loci. Even though single copies might provide suﬃcient protein level
(haplosuﬃciency), this event is of fundamental importance when one copy is already not
functional. Therefore, loss of heterozigosity of tumor suppressor genes is an event likely to
be fueled by chromosome loss.
In both TI-Her2 and TI-Her2/Mad2 samples, there was statistically signiﬁcant diﬀerence
comparing the average loss rate versus the average gain rate of samples from the same geno-
type (two samples test for equality proportions with continuity correction, p-value= 0.01286
and 0.00473 respectively). Considering the average of gain and loss per chromosome per
genotype, chromosome 3 and 18 are gained at higher rates in TI-Her2 primary tumors (p-
value=0.0292 and 0.0002 respectively). TI-Her2/Mad2 samples instead show a speciﬁc gain
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of chromosome 6 (p-value=0.0001).
As far as losses are concerned, chromosomes 1, 2, 7, 8, 9, 11, 12, 15, 16 and 19 are lost
speciﬁcally in TI-Her2 samples, while chromosome 4, 14, 18 are lost at higher rates in the
TI-Her2/Mad2 genotype. It is worth to notice that chromosome 4 and 14 tend to be lost -
rather than gained - also in TI-Her2 primary tumors, however, these events happen at stati-
stically signiﬁcant higher rates when in combination with Mad2 over-expression (Figure 3.10
E). Thus, it seems that events favoring Her2 driven tumorigenesis are exacerbated in triple
transgenic mice. What is the advantage should depend, of course, on the genes encoded by
these chromosomes.
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Figure 3.10: Mad2 over-expression causes higher rates of whole CIN. A) Distribution of cells
(%) according to chromosome number content (control white, TI-Her2 green, TI-Her2/Mad2 blue). B)
Percentage of cells with at least one missegregation event in TI-Her2 and TI-Her2/Mad2 primary tumors
(Fisher's exact test, p-value=0.0246). C) Percentage of cells with no missegregation events (white), mild
missegregation events (1 to 5, light grey) and severe missegregation events (more than ﬁve, black). The
distribution is not diﬀerent across TI-Her2 and TI-Her2/Mad2 primary tumors (Fisher's exact test, p-value>
0.05). D) Average percentage of rearranged chromosomes in TI-Her2 and TI-Her2/Mad2 is not statistically
diﬀerent across the two genotypes (Fisher's exact test p value>0.05). E) Average percentage of cells bearing
gained/lost chromosomes in TI-Her2 and TI-Her2/Mad2 primary tumors.
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Another key question is if Mad2 over-expression causes not only whole chromosome CIN
but segmental CIN as well. For this reason, we analyzed the rates of translocated and
derivative (that is a chromosome bearing rearrangements within itself) chromosomes. In
this case, in order to correct for chromosomes gain/loss and 4n cells, rates were calculated
with the actual number of chromosomes of analyzed samples (Figure 3.10 D). We did not
ﬁnd statistical diﬀerences between TI-Her2 and TI-Her2/Mad2 samples considering either
derivative or translocation rates separately (Fisher's exact test). Total rearrangements rates
did not give any statistical signiﬁcance too (Fisher's exact test). In the same way, analysis
of clonal events did not highlight any higher incidence of sporadic events in TI-Her2/Mad2
samples. This means that Mad2 over-expression in our model of breast tumorigenesis did
not elicit higher segmental chromosome instability, which is already present in Her2 samples.
3.3 Mad2 over-expression accelerates tumor relapse
Tumor resistance is the major problem currently faced in the clinic. Patients are either
inherently resistant to drugs or, in most of the cases, develop secondary resistance after
treatment rendering unfruitful any already experienced therapy. Tumors will eventually
resume growth in the same site where the primary tumor was found leading to relapse.
Therefore, trying to understand molecular mechanisms underlying resistance is of utmost
importance.
As previously mentioned, CIN is a common characteristic in tumor relapses and, when
present in the primary tumor, it has been associated with shorter disease free survival,
metastatic spread and therapy resistance (Smid et al., 2010). In this sense, unstable aneu-
ploidy acts as a tumor-promoting event. Concurrently, it should also be remembered that
high CIN rates might exert a detrimental eﬀect on cellular ﬁtness, up to be incompatible
with cellular viability. Thereof, the outcome of diﬀerent levels of aneuploidy will depend on
a speciﬁc organism and cell type.
This is why targeting mitotic cell division has been used as therapeutical concept. The use
of microtubule destabilizing agents (i.e. paclitaxel, vincristine, vinc alkaloids. . . ), aimed at
disturbing mitotic spindle formation and chromosome segregation, has been introduced and
approved by the FDA since the last decade. Upon tubulin binding, microtubule-targeted
polymerizing agents (MTPAs) perturb mitotic spindle stability, mitotic arrest in the cell
cycle and G2/M transition (Bhalla, 2003). Several mechanisms of resistance have been di-
scovered (Orr et al., 2003), underlying the fact that an optimal level of CIN should exist
in order to promote tumor heterogeneity and drug resistant clone selection and avoid cell
death. In breast cancer patients, MTPAs are administered as adjuvant chemotherapy treat-
ment together with targeted therapy, when available (Garrison et al., 2007; Liberato et al.,
2007). Of note, Her2+ breast cancers, whose progression is correlated with CIN (Smid et al.,
2011), seem to be intrinsically resistant to this type of drugs (Tan et al., 2002); moreover,
MTPAs are ineﬀective in genomic unstable relapses.
As piece of evidence from mouse models, Mad2 over-expression in combination with KrasG12D
in the lung favored tumor relapse after oncogene withdrawal (Sotillo et al., 2010). Primary
tumors and, even more, relapses were shown to be highly aneuploid. Therefore, CIN in pri-
mary lesions was the trigger promoting higher rates of recurrences and escape from oncogene
addiction. MRI monitoring conﬁrmed complete regression of primary tumors and recurrence
in the same anatomical position.
In case of breast cancer mouse models, tumor size can be simply monitored by palpation. As
explained in Materials and Methods, when primary tumors reached a size deﬁned as human
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endpoint, transgenic mice were set back to a normal food diet, thus switching oﬀ transgene
expression. We ﬁrst wanted to address if doxycyline withdrawal will allow complete primary
tumor regression. This could have two diﬀerent outcomes: on one hand breast tumors could
regress completely and further mutations/events required for tumor relapse could happen
during the regressed state. On the other hand, primary tumors may not completely regress
after oncogenic shock, underlying the existence of therapy resistant clones already in the
primary tumor.
We monitored oncogenic shock consequence in both c-MYC and Her2 mouse cohorts raised
with or without Mad2 combination. In both cases, Mad2 over-expression in the primary
tumor promoted tumor relapse with decreased latency and increased incidence. Since we
found striking diﬀerences between the two oncogenic backgrounds, the results will be pre-
sented separately. The reason for this is the diﬀerent outcome upon doxycycline withdrawal
and preferred relapses mechanisms adopted to overcome transgenic protein expression.
3.4 The TI-MYC and TI-MYC/Mad2 mouse lines
3.4.1 Doxycycline withdrawal did not lead to complete primary tu-
mor regression in the MYC background
It has already been shown that only 40% of c-MYC induced mammary tumors fully regresses
after oncogene de-induction, while the remaining 60% does not regress completely (D'Cruz
et al., 2001, Leung et al., 2011). Of these, 37% partially regressed and resumed growth
within 1-2 months, while 23% showed no regression and remained dormant or continued to
grow even upon doxycycline de-induction.
Since a diﬀerent genetic background could aﬀect these results, we followed a cohort of MYC
induced animals to allow a comparison with mice also expressing Mad2. In our hands
(n=28), 30% of mice that developed a primary mammary tumor, after oncogene withdrawal
regressed to a non-palpable state then eventually relapsed after a median latency period of
75.3 days. 16% of the mice almost completely regressed (tumor diameter < 5 mm) and
then resumed growth (AR+G) after a median latency of 67.6 days. The largest group,
representing 54% of the mice, showed incomplete regression (IR+G) and resumed growth
after 50.4 days. This is in line with previously published data, highliting the fact that, after
oncogene withdrawal, the majority of MYC-driven breast carcinomas do not regress to a
non-palpable state suggesting that they are already independent of the driving oncogene.
In contrast, tumors expressing a combination of MYC and Mad2, (n=18) never com-
pletely regressed after deinduction of these transgenes. In this model, 25% had a conside-
rable reduction in tumor size before starting to grow again (AR+G), while the remaining
75% showed only a minor reduction (IR+G) (median re-growth latency 47.8 days and 31.5
days respectively).
CIN, in the MYC background, is preventing primary tumors from complete regression in
100% of the cases. This underlies the existence of oncogene-independent clones already in
the primary tumor, an event that is even more prominent in TI-MYC/Mad2 mice. Hence,
Mad2 over-expression favored this process and rendered unfruitful any response to mimicked
targeted therapy.
There was no statistical signiﬁcance in relapse latency between the two cohorts (see ﬁgure
3.11 B). This was to be expected, since in both cohorts, no complete primary tumor re-
gression occurs. However, time required for TI-MYC/Mad2 AR or IR (47.8 days and 31.5
days respectively) tumors to resume growth was signiﬁcantly shorter than in the TI-MYC
counterpart (AR TI-MYC 67.6 days, IR TI-MYC 50.4 days. Two way anova).
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Figure 3.11: Doxycycline withdrawal in MYC-driven tumorigenesis lead to incomplete tumor
regression. A) After doxycycline withdrawal, 30% of TI-MYC primary tumors (n=28) regressed to a non
palpable state while the remaining 70% never completely regressed. None of TI-MYC/Mad2 mice completely
remitted primary malignancies (n=18). B) Kaplan Meyer plot of relapse latency in TI-MYC (green) and
TI-MYC/Mad2 mice (blue; Mantel-Cox test, p-value>0.05). The blue line close to the y axis represents
100% of the events for the TI-MYC/Mad2 cohort, which has no relapse latency since primary tumors never
reached complete regression. In case of TI-MYC malignancies, 70% of the events is represented by the green
line close to the y axis (AR and IR tumors). Relapse latency (days) for TI-MYC samples that completely
regressed is afterwards plotted. C) Time (days) required for almost completely (AR, grey) or incompletely
regressed (IR, white) tumors to resume growth (R) after doxycycline withdrawal.
3.4.2 Mechanism of relapse in MYC driven breast tumorigenesis
Previous studies in TI-MYC breast carcinogenesis (D'Cruz et al., 2001, Leung et al., 2011)
have highlighted that primary tumors acquire independence from the driving oncogene by
preferential mutations in the Kras2 endogenous locus. 80% of tumors that did not show sign
of regression after removal of c-MYC carried a mutation in Kras2 (Leung et al., 2011). Alter-
natively, other members of the Ras family, Hras or Nras were aﬀected whenever mutations
in Kras2 were not detected (D'Cruz et al., 2001).
Therefore, we sequenced the Kras endogenous locus in the TI-MYC/Mad2 non regressing
primary tumors, and observed that it was mutated in 37.5% (n=6) of the cases. Mutational
analysis in both Hras and Nras endogenous loci was carried out in all the samples, and never
these genes were found to bear spot mutations, unlike published data in TI-MYC model.
In 12.5% of the cases mutations occured in the rtTA region, allowing transgenes re-expression.
In fact, in tetracycline inducible mice, a published mechanism of re-addiction to the initial
driving oncogene occurs via point mutations of the rtTA element, converting the system
from Tet-ON to Tet-OFF (Urlinger et al., 2000, Manfred Gossen, 1995, Winfried Hinrichs,
1994, Podsypanina et al., 2008).
The remaining samples (n=8), did not show any of these mutations. However, 37,5% of
TI-MYC/Mad2 recurrences showed transgenes re-expression (conﬁrmed by IHC analysis),
despite not being associated with a mutation in the rtTA region. This highlighted the de-
pendency of primary tumors to the initiating lesion and the possibility of ﬁnding diﬀerent
mechanisms to make this happen.
Histopathological analysis of TI-MYC (n=24) and TI-MYC/Mad2 (n=19) recurrences did
not show striking diﬀerence in classiﬁcation. In fact, in both genotypes, the two main
types of tumor phenotype observed were papillary and EMT (TI-MYC: 62.5% and 37.5%
respectively; TI-MYC/Mad2: 36.8% for both types). Only in case of TI-MYC/Mad2 non
regressing tumors, some of them (26.4%) were classiﬁed solely as solid carcinomas. Neverthe-
less, in TI-MYC/Mad2 samples we could observe a correlative trend in tumor histopathology
and the type of mutation occurring in recurrent tumors. In fact, EMT or spindled carcinoma
samples were characterized only by mutations in the endogenous Kras gene or did not show
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Figure 3.12: Mechanism of relapse and histopathology of TI-MYC and TI-MYC/Mad2 mouse
lines. Small insets describe mutations found in the sample; if not present, no mutations were discovered in
any of the following genes: Kras, Nras, Hras and rtTA (inset none). A) TI-MYC recurrences preferentially
mutate the endogenous Kras oncogene (panel a,b,c). B) HA (panels e, f, g, h) and MYC (panels i, j, k ,l)
IHC of TI-MYC/Mad2 non regressing tumors. Mutations can be found either in Kras or rtTA (e, f). 50%
of TI-MYC/Mad2 samples did not bear any of these two mutations (g, h). Transgenes re-activation was
observed also in absence of rtTA mutation (g). Scale bar: 50 µm.
any mutation in the analyzed loci. The papillary type was the most heterogeneous and could
bear mutations either in the Kras or rtTA region or none of them. In none of these samples
we could observe transgene re-expression in the absence of rtTA mutation (IHC performed
against the HA tag and MYC exogenous protein). Contrariwise, we could not ﬁnd any mu-
tation in almost all solid carcinomas, the only exception being one example in the Kras gene.
Only in this subclass transgene re-expression could occur even if no mutations were found in
the rtTA region. The molecular mechanism leading to transgene re-expression in this case
is still unknown to us.
The CIN status of these samples was not analysed, however we could hypothesize that Mad2
induced CIN conferred an advantage in relapse in diﬀerent oncogenic backgrounds. A wider
heterogeneity could give primary tumors the luxury of choosing alternative ways to achieve
resistance to targeted therapy.
3.5 The TI-Her2 and TI-Her2/Mad2 mouse lines
3.5.1 Doxycycline withdrawal leads to complete primary tumor re-
gression in Her2 driven tumorigenesis
We have previously described that Mad2 overexpression in the primary tumor in combina-
tion with oncogenic MYC leads to incomplete tumor regression after oncogene withdrawal.
These results prompted us to analyze if this is a general phenomenon induced by Mad2.
We took advantage of TI-Her2 and TI-Her2/Mad2 mice that developed primary tumors and
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removed doxycycline from their diet when tumors reached a size of 20 mm in diameter. In
this case, all tumors completely regressed to a non-palpable state, regardless of the genotype.
However, this could mean not only that mammary glands eﬀectively completely regress, but
also that small cell populations could survive as non-palpable nodules. In fact, nodules be-
come barely palpable through the mouse skin when they reach at least the size of 1 mm in
diameter but cannot be detected with this method if smaller. To verify which hypothesis
could be compatible with our mice, we analyzed freshly regressed mammary glands four
weeks after no residual primary malignancy could be palpated any more. In this timeframe,
it is likely to think that any information from the tissue will be a consequence of the primary
tumor and the regression process, while events leading to relapse should occur later.
Both TI-Her2 and TI-Her2/Mad2 mammary glands looked completely regressed at this stage
(Figure 3.13). Albeit the presence of scar tissue, in most of the analyzed tissues we could
observed mammary ducts formed by an organized layer of cells immersed in fat.
IHC analysis of the HA tag in TI-Her2/Mad2 samples, did not highlight the presence of
Mad2 expression, conﬁrming that doxycycline withdrawal is eﬀective and that there are no
resistant clones arising in the primary tumor that re-express Mad2.
3.5.2 Mad2 induced CIN boosts relapse frequency and decreases
relapse latency
After doxycycline withdrawal and complete primary tumor regression, mice were weekly
monitored to determine the latency of tumor recurrence. Also in this case, primary tumors
that over-expressed Mad2 are more prone to relapse (Figure 3.14). TI-Her2/Mad2 developed
tumor recurrence with a signiﬁcant shorter latency (109 days, n=18) than TI-Her2 mice (155
days, n=13).
Mad2 over-expression not only accelerates tumor relapse, but increases the frequency at
which relapse event are observed in vivo. In our cohort, 28% of TI-Her2 mice are still tumor
free in the timeframe of analysis (500 days) while in TI-Her2/Mad2 mice, the incidence of
tumor relapse is 94.7%. Hence, in our mouse models, Mad2 over-expression in breast primary
tumors helped the selection of drug resistant clones and correlated with worse prognosis, as
it has been shown in human patients.
3.5.3 Relapse histopathology and mechanism of relapse in the Her2
oncogene background
It has already been described that TI-Her2 relapses are histologically characterized by an
EMT (epithelial mesenchymal transition) phenotype (Moody et al., 2005). Cells have a well
distinguished elongated shape, underlying loss of cell polarity, cell-to-cell adhesion and gain
of migratory and invasive properties. We were able to reproduce the above mentioned data
in our cohort of TI-Her2 mice. All the analyzed relapse samples have the characteristic EMT
phenotype (Figure 3.16 A).
TI-Her2/Mad2 relapses (n=17), instead, can be divided, according to histological analysis,
into two classes: 41.17% have an EMT phenotype, while 58.83% are characterized by a solid
carcinoma classiﬁcation (Figure 3.16). The latter is the only one found in human patients.
Therefore, at least in about half of the cases, the combination of Mad2 and Her2 over-
expression in the primary tumor lead to a relapse phenotype that more closely resembles the
human situation.
It is known that Her2 tumors relapse via an up-regulation of the Snail1 transcription factor,
a master EMT regulator (Moody et al., 2005). As in the TI-Her2 case, EMT-like relapses
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Figure 3.13: TI-Her2 and TI-Her2/Mad2 primary tumors regress completely to a non palpable
state upon doxycycline withdrawal. A) H&E staining of 4 weeks TI-Her2 de-induced mammary glands.
B) HA IHC against the exogenous Mad2 protein in TI-Her2/Mad2 regressed mammary glands (4 weeks
de-induction). Scale bar: upper panels 200 µm and lower panels 50 µm.
from the TI-Her2/Mad2 cohort are characterized by up-regulation of the Snail1 trascription
factor (Figure 3.15 A). Since EMT relapses have the same characteristics in both genotypes,
we wondered what would be the peculiarity within the remaining half of TI-Her2/Mad2
relapses.
First, we decided to verify whether these samples showed re-addiction to the oncogenic
pathway that fuelled primary tumor formation in ﬁrst place. As explained in the introduc-
tion, patients become resistant to targeted therapy. However it has been demonstrated that
tumor cells preferentially acquire mutations that bypass drugs mechanism of action, via a
molecular mechanism that alternatively keeps active the signaling from the primary onco-
genic lesion.
To test this, we ﬁrst performed HA IHC against the exogenous Mad2 protein. 75% of solid
relapses showed expression of this transgene and this result was further conﬁrmed by qPCR
analysis of both HA-Mad2 and Her2 transgenes (Figure 3.15). EMT-like relapses never had
transgene re-expression in either genotype.
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Figure 3.14: Relapse latency in TI-Her2 and TI-Her2/Mad2 cohorts. Time point 0 on the x
axis indicates the moment when primary tumors reached humane endpoint size and mice were weaned
from doxycycline. Each stair on the blue (TI-Her2/Mad2) or green line (TI-Her2) represents a mouse that
developed a relapse. TI-Her2/Mad2 had a signiﬁcantly shorter relapse latency compared to TI-Her2 mice
(Mantel-Cox test, p-value= 0.0034).
Since the easiest explanation for transgene re-expression in the Tet system (see 3.4.2) is
the mutation of the rtTA element, we performed mutational analysis in recurrent tumors.
This revealed the presence of point mutations in the rtTA in all - but one - solid Mad2/Her2
relapses with transgene expression, while EMT looking ones did not (Figure 3.16).
Only one solid TI-Her2/Mad2 relapse was not aﬀected by the rtTA mutation and, conse-
quently, did not show any transgene re-expression. This is, indeed, the only example of this
kind of relapse in our cohorts.
As conclusion, the combinatorial expression of Her2 and Mad2 in primary tumors promoted
relapses that, in roughly half of the cases, mimic patient's situation in the clinic. Thus, due
to the tetracycline system we are using, mutation of the rtTA module causes re-addiction to
the oncogenic pathway causative of the primary tumor. This is often a reason why targeted
therapy is ineﬀective in human patients.
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Figure 3.15: qPCR analysis of Snail1 and transgene expression in TI-Her2 and TI-Her2/Mad2
relapses. Analysis of a subset of relapses from TI-Her2 (green) and TI-Her2/Mad2 (blue) cohort; the same
sample was analysed for all the above mentioned genes. A) qPCR Snail1 expression in TI-Her2 and solid or
EMT-like TI-Her2/Mad2 relapses. EMT samples have signiﬁcant higher expression (t-test). B and C) Fold
change values of Her2 and HA-Mad2 transgenes.
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Figure 3.16: Mechanism of relapse in Her2 driven breast tumorigenesis. Histology examples (scale
bar 50 µm) and relative analysis of rtTA sequencing region (FW and RW strand). A) TI-Her2 relapses have
an EMT phenotype and do not mutate the rtTA region. B) TI-Her2/Mad2 relapses have either a solid or
an EMT histology. HA IHC shows the Mad2 transgene re-expression, which is accompanied by mutation in
the rtTA module.
3.5.4 Mad2 over-expression induces higher metastatic potential in
solid tumor recurrences
It is known that human breast tumors preferentially metastasize to the bone, lung or brain
(Kennecke et al., 2010). As mentioned in the introduction, CIN has been associated with
poor patient's prognosis one of the parameters used to determine it, is the time required for
the primary tumor to form distant metastasis.
TI-Her2 mice develop lung metastasis (Moody et al., 2002) which are responsive to doxy-
cyline withdrawal. In mice, metastatic spread takes place preferentially through the blood
vessels, while in humans, this happens mainly through the lymphatic system. This diﬀerence
is intrinsic to the diﬀerent organisms. Despite this, mouse models have proven useful in the
metastasis ﬁeld and can provide a mean to study this phenomenon in a complex organism.
Therefore, we sought to investigate the metastatic potential in case of Mad2 combination
with the Her2 oncogene. To do so, we analyzed lungs from TI-Her2 and TI-Her2/Mad2
primary and recurrent tumors harvested at humane endpoint stage. In primary tumors, we
did not ﬁnd statistical diﬀerence the area of lung tissue occupied by metastasis among the
two genotypes (Figure 3.17). Interestingly in some sporadic cases TI-Her2/Mad2 tumors
metastasized very severely (up to 60% of metastatic lung tissue). It would be interesting to
understand whether CIN inﬂuenced the metastatic potential: which was the aneuploid level
in the primary tumor and if this was higher compared to less metastasis-prone ones. Never-
theless, the variability between triple transgenic mice is high and therefore, cannot account
for a widespread phenomenon in the cohort. The conditions that rendered extremely serious
lung colonization and, subsequently, macrometastasis formation have not been investigated
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Figure 3.17: Mad2 over-expression promotes lung metastasis in TI-Her2/Mad2 solid recurrent
tumors. A, B) Representative pictures of lung metastasis from primary A) or relapse tumors B) in TI-Her2
(upper panels) and TI-Her2/Mad2 mice (lower panels). Upper panels scale bar 200 µm. C) Analysis of
metastatic potential - quantiﬁed as percentage of lung tissue area occupied by metastatic cells - in primary
TI-Her2 (green) and TI-Her2/Mad2 (blue) lungs taken from mice bearing tumors at human endpoint. There
is no statistical diﬀerence ( unpaired t-test, p-value>0.05) between the average of metastatic potential in the
two genotypes. D) Solid TI-Her2/Mad2 recurrent tumors have a higher metastastic potential, compared to
TI-Her2 and EMT TI-Her2/Mad2 relapses (unpaired t-test).
yet. However it would be very interesting to understand whether there is a link between
Mad2 induced genomic aberrations and this phenomenon.
In contrast to lung metastasis in primary tumors, in case of recurrent tumors, we made
a distinction between TI-Her2/Mad2 solid and EMT-looking relapses. EMT recurrences
show a low degree of lung metastasis, indistinguishable from the one of TI-Her2 relapses. In
fact, it has been known for long time that murine EMT breast tumors do not form distant
metastasis but preferentially invade local tissues (Cardiﬀ R.D., 2010).
Solid TI-Her2/Mad2 recurrent tumors, instead, have a median percentage of metastatic lung
tissue that is signiﬁcantly higher of both EMT TI-Her2/Mad2 and TI-Her2 ones. Hence, in
a speciﬁc subset of TI-Her/Mad2 relapses - which is representative of human relapse phe-
notype - Mad2 over-expression in the primary tumor created the conditions to promote the
mutation of the rtTA element. This resulted, in turn, in transgenes re-activation and higher
metastatic potential.
3.5.5 Mad2 induced CIN is not causative of higher DNA damage
levels in primary tumors
Since solid TI-Her2/Mad2 relapses show transgenes re-expression and this is driven by a
mutation in the rtTA transactivator, we sought to determine whether Mad2 over-expression
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would induce higher levels of DNA damage in the primary tumors. Indeed, one could hy-
pothesize that mutations should occur throughout the entire genome, however, given the
system we are using, we are able to have a ﬁnal readout monitoring transgenes de novo
expression. Importantly, this renders tumors still addicted to the original oncogene, a phe-
nomenon frequently observed also in human tumors (see chapter 1).
It has already been shown that CIN cells can have an increased mutational rate (Janssen
and Medema, 2012). This can be due both to DNA double strand breaks and/or defec-
tive DNA repair. In particular, the Mad2 protein has been linked to the nucleotide excision
DNA repair pathway (NER). Mad2 over-expression in cancer cell lines was shown to suppress
phosphorylation of histone H2AX - a known marker of DNA damage - and to competitively
interact with proteins mediating the NER response (Fung et al., 2008).
Hence, to test if Mad2 over-expression could lead to higher amount of DNA damage in
our mouse model, we analyzed primary tumor samples with the Comet technique (for de-
tails see Materials and Methods). This assay allows the quantiﬁcation of DNA damage in
single cells, therefore, giving the possibility of discerning both the global amount of damage
and its variability within the same tumor.
Six distinct TI-Her2 and TI-Her2/Mad2 primary tumors at humane endpoint stage were
analyzed (Figure 3.18). In both genotypes, we could observe a quite spread heterogeneity
in the amount and distribution of DNA damage. Comparison between the average of DNA
damage within the same genotype, did not highlight any diﬀerence between TI-Her2 and
TI-Her2/Mad2 samples (Unpaired t-test, p-value>0.05).
Therefore, Mad2 induced CIN, at least in this model of breast tumorigenesis, may not induce
higher DNA damage. Alternatively, even if Mad2 might have provoked DNA damage, this
result hinted at the fact that most of the lesions could be repaired to such an extent that
rendered them not detectable with this technique.
0
20
40
60
80
100
TI-Her2/Mad2
TI-Her2
control
BA
0
20
40
60
80
100
TI-Her2/Mad2TI-Her2control
%
 t
a
il
 D
N
A
a
v
er
a
g
e
 %
 t
a
il
 D
N
A
TI-Her2/Mad2TI-Her2control
n.s.
Figure 3.18: Mad2 over-expression did not induce higher levels of DNA damage in primary
tumors. A) Box and whisker plot of the % of DNA in comet tails in individual samples; controls (white),
TI-Her2 (green) and TI-Her2/Mad2 (blue) primary tumors. B) Average of DNA damage (% DNA in comet
tail) within control, TI-Her2 and TI-Her2/Mad2 samples.
3.5.6 Study of primary tumors and relative relapses from the same
animal
The analysis of primary and relapse tumor samples, had so far, been performed on malignant
tissues taken from diﬀerent animals. However, this way, it was not possible to study the
evolution of a primary tumor into the corresponding relapse.
For this reason, we sought to investigate this question with two diﬀerent approaches:
1. Biopsies on animals with primary tumors at human endpoint stage,
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2. Injection of single cell suspension of primary tumors into Rag1-/- mice.
With these experiments, we aimed at understanding whether primary tumor histopatholo-
gical phenotype could be predictive of relapse behavior. In particular, we wanted to under-
stand whether the HA status in TI-Her2/Mad2 primary tumors might discriminate relapse
outcome: would the absence of HA expression predict an EMT, TI-Her2 like type of relapse?
3.5.6.1 Analysis of biopsied primary tumors and corresponding relapses
Biopsies on animals with primary tumors at human endpoint stage (TI-Her2 n=11, TI-
Her2/Mad2 n=21) were performed right before the moment they would be set oﬀ dox, then
monitored exactly as non operated mice. Relapse latency did not show diﬀerences between
non-operated and biopsied mice (Biopsied TI-Her2 mice 189 days, biopsied TI-Her2/Mad2
mice 107.5 days. Mantel-cox test, p-value>0.05 compared to corresponding non operated
cohorts) (Figure 3.19). This suggested that, at least in these cohorts, biopsy did not aﬀect
the natural course of relapse in terms of latency. All TI-Her2 mice developed EMT relapses;
while in the TI-Her2/Mad2 cohort, distribution of relapse phenotype among EMT (69%) and
solid types (31%) was shifted towards TI-Her2 like. We cannot exclude the possibility that
the biopsy procedure could have caused an inﬂammatory response that may have altered the
relapse phenotype, skewing it to the EMT type.
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Figure 3.19: Biopsy procedure did not alter relapse latency. Relapse latency in biopsied TI-Her2
(A) and TI-Her2/Mad2 (B) mice did not diﬀer from non operated mice (Mantel-Cox test, p-value>0.05).
Analysis of biopsied primary tumor samples from TI-Her2/Mad2 mice highlighted the
presence of only one HA-negative primary tumor. Despite animals being selected for the
longer primary tumor latency (see paragraph 2.4.1), we were not able to increase those
numbers. Therefore, it was not possible to draw any conclusion in this respect. However,
from results of HA-Mad2 positive biopsies we can infer that this type of primary tumor
has the potential to relapse both as EMT (64% of cases) and solid (36%); therefore, EMT
relapses may arise from both low and high Mad2 expressing cells. qPCR for HA-Mad2 and
Her2 transgenes as well as rtTA mutation analysis gave similar results than non biopsied mice
(Figure 3.20). This conﬁrmed the ability of TI-Her2/Mad2 tumors to speciﬁcally mutate the
rtTA region in order to sustain re-addiction to the Her2 oncogene.
Statistical analysis of Snail1 (unpaired t-test), instead, did not highlight any signiﬁcant
diﬀerence between solid TI-Her2/Mad2, EMT TI-Her2/Mad2 and EMT TI-Her2 relapses.
This is in contrast to what we observed in non biopsied mice (see 3.5.3). In fact, solid and
EMT TI-Her2/Mad2 relapses have comparable levels of Snail1 expression. It is known that
an inﬂammatory response can stabilize the levels of Snail1 (Wu et al., 2009). Therof, even
if we have not proven that the biopsy procedure was eliciting inﬂammatory responses, this
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Figure 3.20: HA status in primary tumors did not predict relapse outcome in TI-Her2/Mad2
mice. A) Histopathological analysis of primary biopsies and corresponding relapses in TI-Her2 (H&E
staining) and TI-Her2/Mad2 (HA IHC) samples. Panels in the top right corner of solid TI-Her2/Mad2
relapses describe mutational analysis of the rtTA region. All the other samples do not bear any mutation.
(Scale bar 50 µm). B) qPCR analysis of Snail1 and transgenes expression. TI-Her2 relapses (green), EMT-
like TI-Her2/Mad2 (plain blue) and solid TI-Her2/Mad2 recurrences (striped blue).
might provide a possible explanation for Snail1 levels becoming homogeneous across all our
samples.
3.5.6.2 Analysis of primary tumors injected into Rag1-/- mice
As mentioned in the previous paragraph, the biopsy procedure itself could generate phy-
siological responses that may change the outcome of relapse. An extreme advantage of the
mammary gland is that it is a transplantable organ. Therefore, we decided to inject single
cell suspension of primary tumor into the mammary gland of Rag1-/- immuno-compromised
mice. At weaning, the development of the mouse mammary gland is not completed yet, and
the mammary tree is still not branched. A procedure of clearance of the mammary tree
originating center leaves the mammary fat pad intact and this can be used to inject cells
into a physiological environment.
Primary tumors from TI-Her2 (n=17) and TI-Her2/Mad2 mice (n=14) were digested into
single cell suspension (see Materials and Methods) then injected into cleared mammary fat
pad of 21 days old Rag1-/- hosts (number of injected cells 250,000 or 500,000 per fat pad).
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After, Rag1-/- mice were monitored under two conditions: in one case, mice were fed with
normal food, thus mimicking oncogenic shock; in the other, mice were kept on a doxycycline
diet until injected cells could grow again into a solid palpable mass and, only then, set back
to a normal diet to switch oﬀ transgene expression.
Of all TI-Her/Mad2 tumors injected, only two of them managed to grow into a solid mass
when the mouse was put oﬀ dox straight after the injection; only one analogous case ap-
peared in the TI-Her2 cohort. This condition, apparently does not allow tumor cells to ﬁnd
an environment amenable to relapse.
The outcome was diﬀerent in the other condition: when mice were set on a doxycycline
enriched diet, in most of the cases a tumoral mass would form with quite short latency (2
to 4 weeks after injection). After doxycycline withdrawal, tumor generally regressed, even
if some never reached the non-palpable state. This discrepancy could be due to the mam-
mary gland sparing procedure itself: as cells were injected when the mammary gland is not
formed, the draining system of the organ never developed, therefore making more diﬃcult
the elimination of dead tissue. Eventually, completely regressed tumors grew into relapses
or non completely regressed ones resumed growth.
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Figure 3.21: Analysis of TI-Her2 and TI-Her2/Mad2 relapses in Rag1-/- mice. A) Primary
tumors and corresponding relapses from TI-Her2 cohort (H&E). In the middle panel, an example of solid
relapse is shown. B) HA IHC of TI-Her2/Mad2 primary tumors and corresponding relapses. Insets describe,
if present, the type of rtTA mutation. Scale bar 50 µm.
In agreement with biopsied mice, relapses arising into Rag1-/- recapitulated what happens
with non-operated animals in TI-Her2/Mad2 cohort. Primary tumors positive for HA-Mad2
IHC had the potential to relapse both as EMT and solid way, and the latter ones had a mu-
tation in the rtTA region that would allow transgenes re-expression. However, the striking
ﬁnding was that the very same pool of injected cells coming from the same primary tumor
could give rise to both types of relapse. What is the event leading to a speciﬁc choice
towards relapse is not clear; when this decision is made is also an interesting point to be
investigated.
Regarding TI-Her2 mice, tumors relapsed via an EMT phenotype. In this case, for the
ﬁrst time, two solid relapses arised but they did not present an rtTA mutation. None of the
relapses coming from TI-Her2 primary tumors beared any mutation.
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Conclusively, these results are conﬁrming what we have already observed in biopsied and
non biopsied mice in terms of relapse. We were able to show that:
 in non biopsied mice, TI-Her2 primary tumors relapse with an EMT phenotype via
the up-regulation of the Snail1 transcription factor, as previously published.
 TI-Her2/Mad2 primary tumors give rise to relapses that can have either an EMT or
solid phenotype. In the ﬁrst case, recurrent tumors have the same characteristics as
TI-Her2 derived ones. When a solid relapse occurs, mutation on the rtTA element
promotes transgenes re-expression. This highlights the dependency of primary tumors
on the oncogenic initiating lesion. Therefore, in our transgenic system, mutation of
the rtTA element is a preferred hijack to sustain tumor growth.
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Chapter 4
Discussion
CIN has been observed in a wide variety of human tumors (Duijf et al. 2012). A recent
study has pointed out that 68% of human solid tumors show unstable aneuploidy. The rates
of whole chromosome aneuploidy vary among tumor types, with brain tumors being chara-
cterized by the highest incidence, most probably because samples are amenable to analysis
only at the very late stages of the disease. In the case of breast tumors, more than 60% of
analyzed samples are aneuploid.
Trying to understand the correlation between aneuploidy, CIN and tumorigenesis is ex-
tremely important. In the case of breast cancer, it represents the second leading cause
of cancer-related death in women worldwide. If prevention, early diagnosis and monitor-
ing of familial cases have improved the timing of neoplasia detection at early in situ stages,
much more still has to be done regarding therapeutical options and, in particular, recurrence.
Mitotic checkpoint genes are frequently over-expressed in human tumors (Carter et al., 2006;
Rhodes et al., 2004; Rhodes et al., 2007) and it has been extensively demonstrated that de-
regulation in their expression is one of the molecular mechanisms generating CIN in vivo
(Diaz-Rodríguez et al., 2008; Schvartzman et al., 2011; Sotillo et al., 2007). In human
tumors, over-activation of the SAC is an event that happens much more frequently than
mutation (Perez de Castro et al., 2007) or partial inactivation. In breast tumors, CIN scores
are highly associated with patients poor prognosis (Carter al., 2006; Smid et al., 2010) and
are thought to favor the generation of tumor heterogeneity and acquisition of resistance to
therapeutical treatments.
In this dissertation, we provide, for the ﬁrst time, evidence for Mad2 driven CIN to play
an opposing role in breast tumorigenesis, in the context of both Her2 and c-MYC onco-
genic backgrounds. Mad2 over-expression, and subsequent over-activation of the SAC in the
process of tumor formation, acts as tumor suppressing event and delays breast tumorigene-
sis. After mimicking perfect targeted therapy, exogenous Mad2 over-expression in primary
malignancies is able to promote tumor relapse, thereof mirroring what happens in human
tumors.
In this chapter, I will discuss the results previously presented and highlight the unanswered
questions arising from this work.
4.1 Mouse modeling of human breast cancer
Mouse models that would recapitulate CIN in an oncogenic background are still scarce
(Janssen and Medema, 2012) and no model has, so far, been published for breast cancer.
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Therefore, we thought that generating a new mouse model, that would faithfully recapitulate
breast tumorigenesis, will be of extreme help in the understanding of this disease.
Unlike previously published results (Sotillo et al., 2007), Mad2 over-expression alone is not
suﬃcient to initiate primary tumor formation in the breast, at least in the MMTV-rtTA
background. Therefore, we crossed tetracycline inducible mice, overexpressing the Mad2
protein in combination with either the Her2 or c-MYC oncogenes speciﬁcally in the mam-
mary gland. As previously mentioned, these are relevant oncogenes in human breast cancers.
Whereas MYC is still not druggable, targeted therapy has been developed against the Her2+
subtype. Nevertheless, despite initial response to trastuzumab treatment, a high percentage
of patients eventually relapse becoming resistant to this antibody.
The mouse models we generated (TI-Her2/Mad2 and TI-MYC/Mad2) allowed us to study
breast tumorigenesis combining both CIN and the concept of oncogene dependence in the
breast. All the steps, from primary tumor formation, progression and relapse could be stu-
died. In particular, these mouse models exactly recapitulate what happens in humans after
targeted therapy treatment - in a realistic scenario for Her2, while potentially predicting
targeted therapy outcome against the c-MYC oncogene. In both cases, Mad2 induced CIN
renders ineﬀective the initial treatment, making these mice a precious tool amenable to study
molecular mechanisms at the source of resistance.
The Her2 oncogene over-expressed in our model was cloned from rat and, unfortunately, is not
recognized by the human monoclonal antibody trastuzumab. However, these mice could be
alternatively treated with other drugs that have been developed to overcome trastuzumab
resistance. These are small molecules inhibitors (such as Neratinib or Laptinib) that are
able to recognize and bind also to rat Her2 and could be given to mice in appropriate reg-
imens. This would have the advantage of uncoupling Mad2 over-expression from oncogene
withdrawal, allowing the persistence of CIN during therapeutic treatment. It would be inte-
resting to understand whether TI-Her2/Mad2 mice would develop relapses with the same or
an even shorter latency in this setting. In the ﬁrst scenario, this would lead to the hypothe-
sis that oncogene independent clones are generated already in the primary tumor, therefore,
the persistence of CIN would not confer any advantage in tumor recurrence. On the other
hand, if relapses occured faster, it would mean that the acquisition of further rearrangements
and/or mutations are required to promote tumor re-growth and that CIN has the capability
of fueling this process.
As far as modeling of the human disease per se is concerned, the simultaneous regulation
of both Mad2 and Her2/c-MYC by doxycycline administration/withdrawal is a feature that
leaves several questions open. For instance: when, during primary tumorigenesis, is CIN
crucial to promote selection of oncogene independent clones? And how would it be possible
to better mimic targeted therapy while still giving CIN the possibility to act on cancer evo-
lution towards resistance?
These questions obviously cannot be answered with the TI-Her2/Mad2 and TI-MYC/Mad2
models since Mad2 over-expression occurs at the same time as the oncogenes. In primary
tumor formation, this means that CIN will be induced since the very early stages. If it is
true that aneuploidy is one of the earliest marks of the disease, which can be detected also
in histologically normal breast tissue, we still do not know if this happens concomitantly
with oncogene deregulation. Since oncogene over-expression has always been depicted as the
driving force of tumor initiation, it has been hypothesized that one event follows the other.
The advent of next generation sequencing has given the opportunity to deeply investigate
this question and now we start having ﬁrst insights from human tumor specimen. In a paper
recently published by Wang and colleagues (Wang et al., 2014) sequencing studies performed
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on two diﬀerent subtypes of human breast tumors revealed that chromosomal rearrangements
deﬁned a monoclonal population, therefore occurred early in tumor evolution. On the other
hand, the mutational landscape evolved gradually generating widespread clonal diversity.
Unfortunately, it is not clear whether aneuploidy could have evolved with co-existing muta-
tions. Hence, if it was clear that two diﬀerent molecular mechanisms operated in the same
tumor, what is still obscure is the sequence of events during tumor evolution. In this regard,
it should be pointed out that all the information we have acquired come from biopsy or ma-
stectomy specimen, which represent later stages in the progression of the disease and force
retrospective types of studies.
Then, when CIN is an established feature of neoplastic lesions, what is the time frame during
which aneuploidy needs to act in order to fuel the selection of therapy resistant clones? The
only way to answer this question lays in the generation of an improved mouse model in which
Mad2 and oncogene over-expression are uncoupled. Therefore, in our lab, new mouse models
- for breast and lung tumorigenesis (M. Jechlinger and C. Aguirre unpublished results) - have
been generated. In these mice Mad2 is under doxycycline regulation, while oncogenes are
controlled by Cre recombinase induction. This way, Mad2 expression can be independently
turned on, at later stages, at diﬀerent timepoints and for diﬀerent timeframes of induction.
Tamoxifen administration will induce the Cre-driven excision of a stop cassette cloned up-
stream the oncogene, thus allowing its constitutive expression without interfering with Mad2
induction. In the same way, doxycycline withdrawal will not aﬀect oncogene over-expression
and, conversely, administration of targeted therapy to mice would not simultaneously shut
oﬀ Mad2 induced CIN. In fact, it is likely that in human patients CIN is still an active
process during treatment. Therefore, in this case, another possible scenario of the disease
could be modeled and investigated.
4.2 Tumor suppressing eﬀects of CIN
As extensively discussed in the ﬁrst chapter of this dissertation, an increasing body of evi-
dence has pointed out the opposing roles of CIN in tumorigenesis: tumor suppressing and
tumor promoting. The tumor suppressive role of CIN has been demonstrated both in yeast
(Torres et al., 2007) and in vivo mouse models (Rao et al, 2005). In particular, Rao et al.
were able to demonstrate the dual role of CIN in the same animal. In fact haploinsuﬃciency
of BubR1 decreased the rate of small intestinal tumors and at the same time promoted colon
tumorigenesis in the APCMin/+.
In a recent mouse model of BubR1 over-expression, mice were protected against tumor
formation even in an oncogenic background (Baker et al., 2012). Both cyclin B1 and B2
over-expression, instead, promoted spontaneous and carcinogen induced tumor incidence
(Nam and van Deursen, 2014).
In the mouse models generated in this dissertation, Mad2 induced CIN has a clear tumor
suppressive eﬀect in primary tumor formation both in the Her2 and c-MYC backgrounds.
Unpublished data from our lab, using a mouse model where Mad2 is expressed in combination
with another oncogene, KrasG12D, led to the same observation (K. Rowald, in preparation).
Moreover, tumor multiplicity was reduced in TI-Her2/Mad2 in comparison to TI-Her2 ani-
mals. These results highlight the hypothesis that Mad2 detrimental role on primary breast
tumorigenesis may be a general eﬀect, which is independent of the oncogenic background
but linked to tissue speciﬁc properties of the mammary gland. In fact, in contrast with
this ﬁnding, no diﬀerence in tumor multiplicity - but acceleration in tumor formation - was
observed in a CIN mouse model of KrasG12D lung adenocarcinoma, as compared to KrasG12D
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mice alone (Sotillo et al., 2010).
In section 2.3, Mad2 over-expression was demonstrated to cause mitotic arrest ex vivo after
a short pulse of induction. This result was further conﬁrmed in vivo (K.Rowald). If these
cells are arrested in mitosis, they will eventually overcome the block and progress through
cell division. Furthermore, these cells will have to adapt to Mad2 over-expression in order
to overcome CIN detrimental eﬀects. As already discussed, the outcome of incorrect mitosis
generates aneuploid cells whose fate depends on the cell type, the extend of genomic imba-
lance and DNA damage that has been generated. Aneuploid cells constitute a danger for a
normal organism, therefore, when the main tumor suppressive pathways are active, they are
detected and driven into apoptosis or senescence. However, in a tumorigenic background,
such as the one generated by oncogene over-expression, already transformed cells will not
readily be eliminated when becoming aneuploid and will, eventually, adapt to Mad2 over-
expression.
Live cell imaging of pre-neoplastic lesions of the mammary gland are still technically very
challenging. Therefore, transgenic primary mammary epithelial cells grown in 3D could be
used as a valid alternative to monitor this phenomenon. In fact, these cells are responsive
to doxycycline induction and can be monitored in time-lapse experiments to understand the
outcome of cell division upon Mad2 over-expression. First cell divisions will give a hint of the
consequences of prolonged mitosis in primary mammary cells, while second or third rounds
may help understanding how, and if, cells can overcome mitotic block. For instance, time
required to complete mitosis may change and allow cells to more readily slip through the
block imparted by Mad2 over-expression.
For this reason, we crossed mice constitutively expressing the H2B-GFP protein with our
bi-transgenic and tri-transgenic mice to perform live cell imaging of 3D cultured cells. This
experiment has proven to be very challenging from the technical point of view, therefore
results are not presented in this dissertation. However, this may be one of the most straight-
forward ways to understand the mechanism of cell adaptation to Mad2 induced mitotic block
and CIN.
It has been demonstrated that Mad2 over-expression is not required for tumor mainte-
nance (Sotillo et al., 2007). This directly correlates with the observation that a subset of
TI-Her2/Mad2 primary tumors do not show Mad2 over-expression at human endpoint stage.
We could hypothesize that Mad2 expression was cell autonomously down-regulated, there-
fore, eliminating detrimental eﬀects of continuous generation of genetic imbalances once an
aneuploid karyotype, favorable for tumorigenesis, has been selected. In fact preliminary re-
sults coming from the analysis of transgenes expression in induced mammary glands and
primary tumors taken from the same animal at humane endpoint stage, highlighted the loss
of Mad2 expression only in breast cancers (see 3.2.4.1). Hence, we could speculate that af-
ter doxycycline induction all mammary glands expressed both transgenes, but the selection
for HA-Mad2 negative clones took place only during tumor formation. Of course, this is
only an indirect correlation and the best way to demonstrate this hypothesis would be the
comparison between initial and humane endpoint levels of induction. Therefore, analysis
of transgenes expression at early pre-neoplastic time points throughout all primary tumor
formation has now been undertaken in the lab (K. Rowald, unpublished results). These
data hint at the hypothesis that whenever Mad2 is over-expressed at high levels cells down-
regulate it to reach average amount of protein. As consequence, this may lead to tolerable
CIN levels that are not detrimental to cellular ﬁtness but promoting tumor heterogeneity
and the selection of therapy resistant clones.
The Weaver lab (Silk et al., 2013) has respectively correlated mild and high aneuploidy levels
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with tumor promoting and tumor suppressing eﬀects in vivo. One backdraw of this study is
that levels of aneuploidy were scored in MEFs and not in cells taken from primary tumors.
Still, both in vitro and in vivo data elegantly supported a dual role for CIN in tumorigenesis
(see 1.3.3).
Nevertheless, the mouse models generated in our lab may underlie a similar phenomenon,
whereby initial high CIN levels are detrimental for tumor formation and therefore, selected
against. After cell autonomous down-regulation of Mad2 expression or selection for cell
expressing an intermediate level, evolution of tolerated tumor promoting karyotypes can
take place. The initial detrimental eﬀect of Mad2 over-expression may explain delayed pri-
mary tumor latency in TI-Her2/Mad2 and TI-MYC/Mad2 mice, while the consequent level
adaptation will allow formation of aneuploid tumors.
4.3 CIN and the generation of tumor heterogeneity
Aneuploidy has long been known to promote tumor heterogeneity. This characteristic is
fundamental to drive the acquisition of therapy resistant karyotypes that would, ultimately,
lead to ineﬀective therapeutic approaches.
In case of MYC driven tumorigenesis, there was no diﬀerence in the histopathological spec-
trum of double and triple transgenic mice both in primary and recurrent tumors. Why Mad2
over-expression was not broadening this phenotype is not clear. As already mentioned (see
1.4.3; Cardiﬀ et al., 2000) GEM tumorigenesis driven by speciﬁc transgenes is characterized
by unique histologies. Thereby, one could speculate that in this case, the MYC oncogene is
the principal determinant of the phenotype and Mad2 over-expression cannot over-ride this
speciﬁcation.
In contrast, in the TI-Her2/Mad2 mouse model we could appreciate a higher heterogeneity
in tumor histopathology, both in primary cancers and relapses when compared with the
TI-Her2 counterparts. In tumor recurrences, solid histopathology was found only in TI-
Her2/Mad2 samples. Human breast cancer relapses are characterized by solid phenotype
only. Therefore, at least in a subset of TI-Her2/Mad2 relapses we were able to recapitulate
the human phenotype. Moreover, these were the only ones that showed re-expression of the
initiating oncogene, a mechanism of relapse that is common in human patients (Berns et al.,
2007; Christianson et al., 1998; Garner et al., 2013).
To investigate whether a histological broader phenotype in TI-Her2/Mad2 mice could be
due to higher genomic aberrations, we analyzed TI-Her2 and TI-Her2/Mad2 primary tumor
karyotypes taking advantage of the M-FISH technique.
Mad2 over-expression in MEFs under the control of the CMV (citomegalovirus) promoter
(Sotillo et al., 2007) is known to induce anaphase bridges, chromosome gains and losses,
chromosome breaks and rearrangements.
Karyotype analysis (Montagna et al., 2002) of Her2/neu induced mammary gland tumors,
in a mouse model where an activated form of the Her2 transgene is expressed under the con-
trol of its own endougenous promoter, highlighted recurrent deletions of chromosome 4 and
genomic ampliﬁcations. Therefore, we wanted to understand whether Mad2 over-expression
in the Her2 oncogenic background would promote higher rates of genomic instability com-
pared to TI-Her2 primary tumors. In conclusion, TI-Her2/Mad2 primary tumors are more
aneuploid and this correlates with more cells missegregating chromosomes in mitosis and
W-CIN.
Suprisingly, there is no statistical diﬀerence in the amount of S-CIN between the two geno-
types. As Mad2 over-expression has been shown to promote the formation anaphase bridges
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and chromosome breaks, it was likely to expect that triple transgenic tumors would be di-
stinguished by a higher rate of rearrangements, detected by M-FISH as translocations or
derivative chromosomes. Why this previous observation has not been found in our model
could be due to diﬀerent reasons. First, TI-Her2 tumors are already per se characterized by
a certain level of chromosome rearrangements and Mad2 over-expression may not aﬀect this
parameter, therefore no diﬀerence is observed. Second, primary tumor samples were col-
lected at human endpoint stage. As discussed in the previous section, tumors need to select
for an optimum level of CIN in order to maintain heterogeneity compatible with cellular via-
bility. Therefore, it might be possible that in breast tumors, once a certain level of CIN has
been reached, it cannot be modiﬁed to avoid eﬀects compromising cellular ﬁtness. Probably,
analysis at earlier time points may reveal pre-existing diﬀerences that are not maintained in
established primary tumors.
One open question is the identiﬁcation of those genomic aberrant clones that will give rise to
tumor recurrence. Karyotyping analysis of relapses may highlight the existence of recurrent
chromosome gains/losses or rearrangements which could be analogous to a subset found in
primary tumors.
Alternatively, we decided to take advantage of 3D cell culture system to grow primary tu-
mor cells into an organotypic environment. The possibility of withdrawing doxycycline from
the culture medium gave us the possibility to mimic oncogenic shock and select for clones
that would grow independently, despite silencing of the oncogene. All cells that had not
already acquired this characteristic would be eliminated by cell death, while allowing the
expansion of clones with the potential of generating a relapse. This selection method has
proved harsh on primary tumor cells. We faced problems in the growth and propagation of
oncogene independent clones. This could be due to the technical procedure itself but may
also hint at the fact that additional mutations are required to promote tumor relapse and,
therefore, the regressed state should be mimicked in culture as well. In fact the mammary
gland is not a resting tissue: female mice are constantly exposed to hormones that regulate
the reproductive cycle from puberty. This results in a periodical expansion of diﬀerent cell
populations, including stem cells. Therefore, an expanding and cycling population could
represent a putative target for cell transformation events at speciﬁc windows of the adult
reproductive cycle (Joshi et al., 2010). This could mean that a static 3D culture system is
not enough to mimic what happens in vivo. As cells should be cycling, subsequent re-seeding
of the 3D gels would force these cells into proliferation and could create the conditions to
acquire mutations.
4.4 Mad2 induced CIN promotes acquired resistance to
targeted therapy
The concept of oncogene dependence (Weinstein and Joe, 2006) describes the addiction of
cancer cells to the sustained expression of the driving oncogenic lesion both for the initia-
tion and the maintenance of the malignant phenotype. Demonstrations of this phenomenon
came from studies on cell lines and mouse models, thus opening the path for the advent of
modern targeted therapy. The past decade has seen the development of many drugs, speciﬁc
inhibitors for over-expressed tyrosine kinase receptors which are currently widely used in
the clinics. For example, Imatinib to cure gastrointestinal stromal tumors and certain types
of leukemias, erlotinib and geﬁtinib targeting EGFR in non small cell lung cancer, sutinib
against VEGF receptors in kidney malignancies and trastuzumab, the already mentioned
monoclonal antibody against the Her2 receptor. All these agents have brought tremendous
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advance in the treatment of cancer disease. Most of them ensure better quality of life during
treatment while others, such as trastuzumab, can also improve overall patient survival and
time to develop recurrence.
However, as already mentioned, those therapies may not be eﬀective for two reasons. First,
the patient is intrinsically resistant to the drug, therefore there will not be any beneﬁt during
its regimen. Second, tumors develop secondary resistance to the drug, eliciting mechanisms
of adaptation and becoming refractory to its function. This leads to the formation of tumor
recurrences which do not respond any more to the initial treatment and, therefore, represent
a major problem in the clinic.
Then, it is of no surprise that a huge eﬀort has been put to understand molecular mecha-
nisms underlying resistance. This is currently one of the most widely investigated question
in the cancer ﬁeld. CIN has been associated with poor patient outcome and short disease
free survival for long time. This observation generated the concept of unstable aneuploidy
as a driving force for tumor heterogeneity and selection of therapy resistant clones.
The ﬁrst mouse model that faithfully recapitulated and demonstrated that CIN is one of the
molecular mechanisms favoring tumor recurrence was published by the Benezra lab (Sotillo
et al., 2010). This phenomenon was modeled generating a mouse over-expressing in a condi-
tional manner Mad2 and KrasG12D oncogene speciﬁcally in the lung. Lung adenocarcinomas
develop only as a consequence of KrasG12D expression and, when in combination with Mad2,
these tumors show a high degree of aneuploidy. As demonstrated by MRI monitoring,
both KrasG12D and KrasG12D/Mad2 primary tumors regress upon oncogene withdrawal. Re-
markably, primary tumors driven by KrasG12D alone never developed recurrence. In striking
contrast, when Mad2 was over-expressed in the primary tumor, 50% of mice relapse, high-
lighting CIN as a potential mechanism to drive the generation of Kras independent clones.
Relapse analysis pointed out a variety of diﬀerentially activated pathways, conﬁrming the
advantage of CIN tumors to select many diverse roads to escape treatment.
Thus, the results presented in this dissertation further conﬁrm this hypothesis, for the ﬁrst
time in a CIN mouse model of breast cancer. In fact, both in TI-Her2/Mad2 and TI-
MYC/Mad2 mice tumor recurrences arose with signiﬁcantly shorter latencies compared to
the double transgenic counterpart. In the case of Her2 driven tumorigenesis, these results
were conﬁrmed also in biopsied mice and transplanted tumor into immune-compromised
hosts.
The mechanisms of relapse were heterogeneous within the same cohort of mice, stressing
again the notion that aneuploidy gives the possibility of choosing alternative pathways to
overcome oncogene withdrawal. As in human patients, in some cases, mutations that alter-
natively re-activate the same oncogenic arm would occur. This observation correlates not
only in Her2+ trastuzumab treated breast cancer patients, but also with EGFR erlotinitib
treated lung cancers. In the last case, a point mutation disabling drug eﬃcacy occurs in the
very same receptor, thus keeping the pathways activated even in the presence of the drug
(Kobayashi et al., 2005; Pao et al., 2005; Politi et al., 2010).
It is widely known that cancer cells have impaired DNA repair pathways (Hanahan and
Weinberg, 2000), thereby providing a fertile soil for the accumulation of mutations. On top
of it, also CIN may help the disruption of DNA repair pathways (Janssen and Medema,
2012). The observation that triple transgenic mice in our cohorts relapse via speciﬁc point
mutations (see 3.4.2 and 3.5.3) lead us to the hypothesis that Mad2 over-expression might
favor this process (Fung et al., 2008). Nevertheless, we could not demonstrate that mice
bearing Mad2 over-expression in Her2 driven primary tumors have higher amount of DNA
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damage (see 3.5.5). The technique we used (see 2.3.3) is a sensitive method to measure at
single cell level single and double strand breaks in DNA. The fact that we could not ap-
preciate stastistical diﬀerence between the average amount of DNA damage in TI-Her2 and
TI-Her2/Mad2 samples might be explained in diﬀerent ways. First, Mad2 over-expression
does not induce higher DNA damage. Second, even if Mad2 induced CIN caused DNA da-
mage, this was repaired and, therefore, not detected. Both points may also correlate with
the fact that TI-Her2/Mad2 primary tumors are not more frequently rearranged than their
double transgenic counterpart (see 3.2.4.2 and 4.3). Third, a diﬀerent technique, such as
sequencing, might be more suitable to adress this question and unravel the presence of dif-
ferent mutational rates between the two genotypes.
Nevertheless, it should be kept in mind that aneuploidy is a valid route for adaptation to
multiple rounds of therapy: it is a constant fuel for the generation of new genomic imbalances
that will mine the eﬃcacy of subsequent and/or combinatorial agents.
4.5 The SAC as a therapeutic target
The mitotic checkpoint is an essential machinery in mammals, both in normal and trans-
formed cells. The idea of the MC as a druggable target has for long been exploited in
the treatment of human tumors. Adjuvant chemotherapeutic treatments against the SAC
are often used in combination with conventional targeted therapy. These drugs target mi-
crotubule polymerization, either stabilizing microtubule dynamics (for instance, taxol) or
promoting their depolimerization (i.e. vincristine and vinblastine). Microtubule targeting
agents have considerable toxic eﬀects, which range from neurotoxicity, thrombocytopenia,
bone marrow suppression to reversible hair loss. This is, of course, a consequence of targeting
such a ubiquitous protein like tubulin. Patients may eventually develop resistance, usually
due to point mutations in the drug binding site of the tubulin monomer (Wang et al., 2005).
All these agents are thought to act on the SAC by perturbing the mitotic spindle and pro-
moting arrest at the metaphase plate. These results came from in vitro studies of cultured
cells (Jordan et al., 1993). Mitotic block is not a condition that can be indeﬁnitely main-
tained and, eventually, cells will slip through. Consequences of mitotic block depend on the
cell type and may vary even among the cells belonging to the same organ (Das et al., 2001).
After prolonged mitotic block, cells may die during mitosis, slip through and subsequently
undergo apoptosis during interphase or progress in the cell cycle to diﬀerent rounds of mito-
sis. Aneuploid cells may anyhow not be eliminated, especially in the fertile soil of mutated
genetic background of pre-neoplastic lesions. Therefore, if, on one hand, microtubule tar-
geting drugs usually have strong therapeutic eﬀect at the beginning of the treatment, on
the other, they may also promote tumor progression through the selection of karyotypically
unstable clones.
Contrariwise an increased mitotic index does not seem to be a requirement - at least for
taxol eﬃcacy - at the concentration measured in vivo. Zasadil and colleagues (Zasadil et al.,
2014) demonstrated that tumor cells taken from breast cancer patients, who received taxol
treatment, do not necessarily undergo mitotic arrest. Tumor cell death was caused by the
formation of multipolar spindles, which, in turn, resulted in chromosome missegregation and
generation of aneuploid cells.
Moreover, the concept of diﬀerent levels of aneuploidy as tumor promoting or suppressive
should be carefully taken into account. As quite promoted therapeutic approach, it must be
kept in mind that it still has obscure dynamics and should be further investigated.
We know that high levels of CIN are usually not well tolerated and induce higher rates of
cell death (Silk et al., 2013) but what this exactly means in terms of actual frequency of
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missegregation events is not clear. We still do not know which is the threshold of instability
that once overcome will inevitably induce cell elimination. Furthermore, it should be con-
sidered that diﬀerent cell types may be sensitive to diﬀerent CIN levels, so each case should
be treated diﬀerently. Then, how this would practically be achieved in patients is yet not
clear. The right drug concentration should be speciﬁcally and equally delivered only to the
tumor mass to avoid oﬀ target eﬀects and dose dependent responses.
Cancer cells are usually characterized by an over-activation of the mitotic checkpoint. There-
fore, if a concept analogous to oncogene-dependence should be exploited, then inhibition of
the mitotic checkpoint may have therapeutic results as well. This approach gave promising
results in glioblastoma cultured cells (Tannous et al., 2013). When the Mps1 mitotic kinase
was inhibited, cells became more sensitive to vincristine treatment. The combination of
these two agents promoted mitotic over-ride, increased aneuploidy and enhanced cell death.
Even though these results are promising, it is still not clear how targeting of tumor cells
only could be achieved in patients. Nevertheless, these ﬁndings open new possibilities in the
treatment of CIN tumors.
We still do not completely understand the molecular mechanisms underlying the relationship
between tumor biology, CIN and therapy resistance. Great improvements have been made
since Boveri ﬁrst postulated that an abnormal karyotype could give rise to malignant cells.
However, more research is needed to unravel mechanistic details of CIN mediated resistance,
so that new and more eﬀective drugs will be developed. Hopefully, this will have profound
impact in the management of cancer disease and prevention of tumor relapse.
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Conclusions
As conclusive part for this dissertation, I will resume here the main parts of this work. These
are sort of take home messages to highlight the most important ﬁndings of this research.
 Mad2 over-expression acts as tumor suppressive factor in breast
tumorigenesis
The generation of new mouse models of breast cancer that recapitulated both oncogene
dependence and chromosome instability provided the base to study breast tumorige-
nesis in a physiologically relevant model. The combined over-expression of Mad2 and
either the c-MYC or Her2 oncogene upon completion of mammary gland development
highlighted the suppressive role of exogenous Mad2 in primary tumor latency. There-
fore, from this study we can conclude that Mad2 over-expression is detrimental in
breast tumor formation and this eﬀect is tissue dependent.
 Mad2 over-expression promotes aneuploidy and tumor hetero-
geneity
As previously published (Sotillo et al., 2007), Mad2 over-expression causes an over-
activation of the mitotic checkpoint, generating chromosome gains/losses, anaphase
bridges and diﬀerent types of rearrangements.
Over-expression of an activated form of the Her2 oncogene in mouse (Montagna et al.,
2002) promotes a certain level of aneuploid in primary tumors. Therefore, we wanted
to understand whether combined Mad2 over-expression promotes higher levels of aneu-
ploidy. Indeed, TI-Her2/Mad2 are signiﬁcantly more aneuploid and are more prone
to missegregation errors. Mad2 eﬀect increased whole chromosome missegregation but
did not aﬀect segmental CIN.
Hence, Mad2 over-expression promotes higher genomic heterogeneity which is also re-
ﬂected by tumor histopathology.
 Mad2 induced CIN induces therapy resistance
Aneuploid human tumors have poor prognosis and require shorter timeframe to re-
lapse. Also in our mouse models, when the Her2 or MYC oncogene are co-expressed
with Mad2, the time required for tumor recurrence is signiﬁcantly shorter than in mice
bearing the oncogene alone.
Chromosome instability is one of the mechanisms able to promote the selection of
oncogene independent clones, that are refractory to targeted therapy treatment. This
results conﬁrms what has been previously published in a CIN mouse model of lung
adenocarcinoma. Thus, a general role for Mad2 over-expression in promoting tumor
relapse is highlighted.
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 Mad2 induced CIN promotes heterogenetity in the mechanisms
of relapse
TI-Her2/Mad2 and TI-MYC/Mad2 mice relapse over a variety of diﬀerent molecular
mechanisms. One possible explanation is that Mad2 over-expression in primary tu-
mors generated the heterogeneity necessary to opt for alternative choices to relapse.
Therefore, CIN oﬀers the luxury of choosing among diﬀerent molecular mechanisms
to achieve oncogene independence. This notion translated into targeted therapy resi-
stance in human patients.
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Conclusiones
Como conclusión del trabajo aquí presentado, paso a resumir los puntos cruciales del proyecto.
 La sobreexpresión de Mad2 actúa como supresor tumoral en
mama
La generación de un nuevo modelo murino de cáncer de mama nos ha permitido recapit-
ular tanto la dependencia oncogénica como la inestabilidad cromosómica, estableciendo
la base para el estudio de la tumorogenesis en mama en un modelo ﬁsiológicamente
relevante. La sobreexpresión de Mad2 en combinación con dos oncogenes diferentes,
c-MYC y Her2, nos ha permitido demostrar el papel supresor de Mad2 durante el
desarrollo de tumores primarios de mama. Podemos concluir, por tanto, que la sobre-
expresión de Mad2 es prejudicial para el desarrollo de tumores primarios de mama.
 La sobreexpresión de Mad2 actúa como promotor de aneuploidía
y favorece la heterogeneidad en tumores de mama.
Como se publicó anteriormente (Sotillo et al., 2007), la sobreexpresión de Mad2 provoca
una hiperactivación del punto de control mitótico (SAC), dando lugar a perdidas y
ganancias de cromosomas, aberraciones en anafase y diversos tipos de anomalías cro-
mosómicas estructurales. La sobreexpresión de la forma activada del oncogén Her2 da
lugar a ciertos niveles de inestabilidad cromosó mica en tumores primarios (Montagna
et al., 2002). Uno de nuestros objetivos, por tanto, ha sido analizar si la sobreex-
presión combinada de Mad2 y dicho oncogén provoca un aumento en los niveles de
aneuploidía. Hemos podido conﬁrmar que los ratones TI-Her2/Mad2 presentan nive-
les signiﬁcativamente mayores de aneuploidía y una mayor tendencia a errores en la
segregación cromosómica. Mad2 inﬂuye especíﬁcamente los errores en la segregación
de cromosomas completos pero no así en la CIN segmental. Podemos concluir que la
sobreexpresión de Mad2 promueve un aumento en la heterogeneidad genómica dando
lugar a alteraciones en la histopatología de los tumores.
 La inestabilidad cromosómica causada por la sobreexpresión de
Mad2 otorga resistencia a la terapia clínica
Los tumores humanos aneuploides presentan una peor prognosis y requieren de un
corto periodo de tiempo para dar lugar a recidivas. Del mismo modo, en nuestro mod-
elos animales donde los oncogenes Her2 o MYC fueron co-expresados junto con Mad2,
el tiempo requerido para la aparición de la recidiva fue signiﬁcativamente menor al
compararlo con aquellos que únicamente sobreexpresaban el oncogén. La inestabilidad
cromosómica es uno de los mecanismos capaces de promover la selección positiva de
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clones que crecen independientemente de la presencia del oncogén y que son, de esta
forma, resistentes a la terapia dirigida. Cabe destacar, por tanto, el papel de la sobre-
expresión de Mad2 en el proceso de recidivas tumorales.
 La inestabilidad cromosómica inducida por Mad2 promueve het-
erogeneidad en las recidivas tumorales.
Los modelos de ratón TI-Her2/Mad2 y TI-MYC/Mad2 sufren recidivas a través de
diversos mecanismos moleculares. Una de las posibles razones es que la sobreexpresión
de Mad2 en tumores primarios otorgue la heterogeneidad necesaria para optar a difer-
entes alternativas que permitan el desarrollo de recidivas. Por tanto, la inestabilidad
proporcionaría un escenario perfecto para la selección de diversas vías que permitieran
la selección de clones independientes de la expresión del oncogén.
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